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1 SUMMARY / ZUSAMMENFASSUNG 
Epoxide hydrolases are enzymes that catalyze the hydrolysis of epoxides to their corresponding diol 
by the addition of a water molecule. The most prominent and best investigated human epoxide 
hydrolases are microsomal epoxide hydrolase (mEH) and soluble epoxide hydrolase (sEH). The role 
of these enzymes for the human organism is at least of dual function. Historically, these enzymes 
were regarded as responsible for the detoxification of potential harmful epoxides. However, intensive 
research over the last decade has proven that they also act on endogenous lipid derived epoxides, an 
important class of signaling molecules. They thereby contribute to the regulation of physiological 
processes. Both enzymes belong to the α/β hydrolase fold super family and share characteristic 
sequence motives that are conserved among all α/β hydrolase fold epoxide hydrolases. By using 
these highly conserved sequence motives as query for Blast searches of the human genome, putative 
novel epoxide hydrolases can be discovered. Recently, our group identified two novel epoxide 
hydrolase genes – EPHX3 (EH3) and EPHX4 (EH4). This raises the following questions that are 
addressed in the present thesis: 
a) Is EH4 an enzymatically active epoxide hydrolase? 
b) What is the substrate spectrum of EH3 and what can we learn from this? 
As a first step to characterize EH4, different prokaryotic and eukaryotic expression systems were 
established in order to investigate EH4 enzymatic activity towards various epoxide substrates and to 
generate an EH4 specific antibody. Rabbit immune sera obtained after immunization, with either 
truncated protein that was recombinantly expressed in E. coli or synthetic EH4 peptides, failed to 
specifically detect EH4. As an alternative method, LC-MS/MS based peptide analysis was established, 
which allowed detection of EH4 in insect cell lysates. To investigate the enzymatic activity, 
recombinant EH4 expressed in E. coli and insect cells was incubated with different radiolabeled and 
unlabeled epoxides and the presence of the respective enzymatic products was analyzed by 
autoradiography and LC-MS/MS. There was no significant reproducible difference in the amount of 
diol in EH4 lysates detectable as compared to the control. In vivo expression analysis in mouse 
revealed presence of EH4 mRNA in the brain, which is in agreement with the data available on 
expression databases. Experiments to determine the subcellular localization of EH4 suggest that EH4 
is membrane associated, which confirmed the prediction that the N-terminal amino acids of EH4 
display a membrane anchor. 
In order to analyze the relevance of EH3 for the human organism, the substrate spectrum was 
assessed and the kinetic parameters of selected substrates were determined. The activity towards 
lipid derived epoxides was investigated in cell lysates of EH3 expressing Sf9 cells and analyzed by 
LC-MS/MS. EH3 was found to be capable of hydrolyzing a variety of different arachidonic acid and 
linoleic acid derived epoxides with proven biologic activity. Among the tested epoxides, 
epoxyeicosatrienoic acids (EETs) and leukotoxin were identified as the best substrates for EH3. The 
catalytic efficiency of EH3 towards these substrates is comparable to that of mEH and sEH. EETs 
have important biological effects on blood pressure, inflammation, pain perception and insulin 
secretion, whereas the linoleic acid derived leukotoxin is involved in the development of a severe 
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pulmonary injury, called adult respiratory distress syndrome (ARDS). Due to its important role in 
turnover of EETs, sEH became a pharmaceutical target. A series of specific sEH inhibitors (sEHi) was 
developed for the treatment of hypertension, inflammatory diseases, pain and diabetes. A set of 
established sEHi was tested towards their effects on EH3 enzymatic activity. Inhibition experiments 
showed, that EH3 was inhibited by a subclass of this urea derived compounds at a concentration that 
is usually employed for in vivo inhibition of sEH.  
In a comprehensive series of experiments, enzymatic activity of EH4 towards the tested epoxides 
could not be proven. Possible reasons are (i) inactive expression of the protein as a result of incorrect 
folding or (ii) the tested epoxides are no substrates for EH4. Further research is required to unveil the 
physiological substrate of this novel enzyme and its role for the human organism. Based on the results 
obtained in this work, the role of EH3 can be ascribed to physiological regulation by turnover of 
endogenous epoxides. The enzyme is capable of converting different fatty acid derived signaling 
molecules, which recently gained interest and are now intensively investigated. The fact that fatty acid 
like inhibitors affect enzymatic activity of EH3, whereas structurally different established sEHi do not, 
further indicates that EH3 preferentially acts on lipid derived epoxides and thus is relevant for 
regulation of physiological processes in the human body. Inhibition of sEH by selective sEHi can 
exploit the beneficial effects of EETs and is a promising target for the treatment of hypertension, pain 
and diabetes. Most certainly it must be taken into account that some inhibitors are not sEH specific but 
rather equally affect EH3, and thus have an additional target with different expression pattern. This 
leads to a modified biological activity as compared to sEH-selective compounds. Importantly, the 
hydrolysis product of leukotoxin has been reported to be a potent mediator of ARDS, a lung injury that 
can result in multiple organ failure. The kinetic data on leukotoxin turnover by EH3 and the fact that 
EH3 is expressed in the lung, strongly suggest a role of this enzyme in ARDS. The generation of an 
EH3 knock out mouse would be a good approach to study the expression and regulation of EH3 and 
to unveil the physiological role of EH3. Detailed analysis of the substrate spectrum will give more 
insight into the role of EH3 as physiological regulator and thereby might enable understanding of 
different diseases and hence the development of novel therapeutics.  
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ZUSAMMENFASSUNG 
Epoxidhydrolasen (EH) sind Enzyme, welche die Hydrolyse von Epoxiden zu ihren entsprechenden 
Diolen katalysieren. Die beiden bekanntesten Epoxidhydrolasen, die cytosolische EH (sEH) und die 
mikrosomale EH (mEH), sind für den menschlichen Organismus in zweierlei Hinsicht von Bedeutung. 
Zum einen sind Epoxidhydrolasen historisch gesehen detoxifizierende Enzyme, die als für die 
Entgiftung potentiell schädlicher Epoxide verantwortlich galten. Innerhalb der letzten Jahrzehnte 
wurde jedoch gezeigt, dass beide Enzyme auch in der Lage sind endogene, biologisch aktive Epoxide 
umzusetzen und damit auch in die Regulation physiologischer Prozesse eingreifen. Epoxidhydrolasen 
sind Mitglieder der sogenannten „α/β-hydrolase fold“- Familie und weisen die für Enzyme dieser 
Familie charakteristischen Sequenzmotive auf. Diese Motive können herangezogen werden, um in 
humanen Genomdatenbanken nach neuen Mitgliedern der α/β - hydrolase fold EH´s zu suchen. Zwei 
neue EH-Gene, EPHX3 (EH3) und EPHX4 (EH4), wurden vor kurzem in unserer Gruppe identifiziert. 
Daraus resultierend stellen sich die beiden folgenden Fragen, welche in dieser Arbeit beantwortet 
werden sollen:  
a) Besitzt EH4 eine Epoxidhydrolase - Aktivität? 
b) Welches Substratspektrum besitzt EH3 und was können wir daraus lernen? 
Für die Charakterisierung der EH4 wurden verschiedene prokaryotische und eukaryotische 
Expressionssysteme entwickelt und etabliert, um einerseits einen Antikörper gegen EH4 herzustellen 
und andererseits die enzymatische Aktivität des neuen Enzyms untersuchen zu können. Immunseren 
von Kaninchen zeigten nach Immunisierung mit entweder einem verkürzten Protein oder 
synthetischen Peptiden, keine spezifische Immunreaktivität gegenüber EH4. Als Alternative wurde 
eine LC-MS/MS basierte Methode entwickelt, die einen genauen Proteinnachweis von EH4 aus 
Zellysat ermöglicht. Für die Analyse der enzymatischen Aktivität von EH4 wurde das rekombinante 
EH4-Protein zuerst mit verschiedenen radioaktiv markierten und unmarkierten Substraten inkubiert, 
um im Anschluss daran die Anwesenheit des entsprechenden Produktes (Diol) mittels 
Autoradiographie und LC-MS/MS zu analysieren. Im Vergleich zu Kontroll-Lysaten war in EH4 - 
Lysaten kein signifikanter Unterschied in der entsprechenden Diol-Menge nachzuweisen. Eine 
Analyse des in vivo Expressionsmusters von EH4 in verschiedenen Organen der Maus, ergab eine 
deutliche Expression von EH4 im Gehirn. Dies steht mit den vorliegenden Daten der 
Expressionsdatenbanken im Einklang. Experimente zur Untersuchung der sub-zellulären Lokalisation 
von EH4 lassen vermuten, dass EH4 ein Membran-assoziiertes Protein ist. Dies bestätigt die 
Voraussage einer in silico Untersuchung die besagt, dass EH4 wahrscheinlich ein 
membrangebundenes Enzym darstellt, da die N-terminalen Aminosäuren Charakteristika eines 
Membranankers aufweisen. 
Um beurteilen zu können, welche Rolle EH3 für den menschlichen Organismus spielt, wurde das 
Substratspektrum untersucht und die kinetischen Parameter einiger wichtiger Substrate bestimmt. Wie 
Untersuchungen zur enzymatischen Aktivität von EH3 in rekombinanten Insektenzellen zeigten, ist 
EH3 in der Lage verschiedene Epoxide der Arachidon- und Linolsäure umzusetzen. Von diesen 
biologisch aktiven Signalmolekülen werden Epoxyeicosatriensäuren (EETs) und Leukotoxin am 
besten umgesetzt. Die katalytischen Parameter der Umsetzung von physiologisch relevanten EET- 
Regioisomeren sowie von Leukotoxin wurden ermittelt, und mit denen von mEH und sEH verglichen. 
ZUSAMMENFASSUNG 
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Das Ergebnis zeigt, dass die katalytische Effizienz von EH3 mit derjenigen von mEH und sEH 
vergleichbar ist. EETs sind Signalmoleküle und haben einen wichtigen Einfluss auf Blutdruck, 
Entzündung, Schmerzwahrnehmung und Diabetes. Leukotoxin hingegen spielt eine Rolle bei der 
Entstehung von ARDS (acute respiratory distress syndrome), einem schwerwiegenden 
Lungenversagen, das als eine Folge von direktem oder indirektem Lungenschaden auftritt. Aufgrund 
der wichtigen Rolle der sEH im Umsatz von biologisch aktiven endogenen Epoxiden, im Besonderen 
im Umsatz von EETs, wurde eine Reihe von sEH- Inhibitoren (sEHi) entwickelt, die zur Behandlung 
von Bluthochdruck, Entzündung, Schmerz und Diabetes eingesetzt werden sollen. Einige dieser 
verschiedenen Verbindungen wurden auf ihre inhibitorische Wirkung gegenüber EH3 getestet. Die 
Untersuchungen ergaben, dass das Enzym von einer bestimmten Gruppe dieser Inhibitoren gehemmt 
wird, und zwar in einem Konzentrationsbereich der auch in vivo in eingesetzt wird.  
Eine enzymatische Aktivität von EH4 gegenüber den getesteten Substraten war in einer umfassenden 
Reihe von Experimenten nicht nachzuweisen. Mögliche Erklärungen dafür sind i) das Protein ist falsch 
gefaltet und von daher inaktiv exprimiert oder ii) die getesteten Epoxide sind keine Substrate für EH4. 
In jedem Fall sind weitere Untersuchungen nötig, um die physiologischen Substrate von EH4 zu 
identifizieren und die Rolle des Enzyms für den humanen Organismus zu enthüllen. Die Ergebnisse 
zur Untersuchung des Substratspektrums sowie des Inhibitorprofils von EH3 weisen darauf hin, dass 
EH3 durch den Umsatz von endogenen biologisch aktiven Epoxiden eine wichtige Rolle in der 
physiologischen Regulation spielt. Das Enzym ist in der Lage eine Reihe verschiedener biologisch 
aktiver Epoxide umzusetzen, welche in letzter Zeit zunehmend an Interesse gewinnen und aktuell 
intensiv erforscht werden. Zudem ist die Tatsache, dass nur Inhibitoren mit struktureller Ähnlichkeit zu 
Fettsäuren die enzymatische Aktivität von EH3 beeinflussen, ein weiterer Hinweis auf das 
Substratspektrum und die Funktion von EH3 für die Regulation physiologischer Prozesse im 
menschlichen Organismus. Die Inhibierung der sEH durch spezielle sEH- Inhibitoren (sEHi) stellt eine 
Möglichkeit dar, die positiven Wirkungen der EETs zu nutzen und als therapeutischen Ansatz für die 
Behandlung von Bluthochdruck, Entzündung, Schmerz und Diabetes einzusetzen. Wie die Ergebnisse 
der Arbeit zeigen muss jedoch berücksichtigt werden, dass mit großer Wahrscheinlichkeit einige sEH-
Inhibitoren unspezifisch sind und ebenfalls eine Wirkung auf EH3 haben. Ein zusätzliches Target, 
dass verglichen mit sEH ein anderes Expressionsmuster und Substratspektrum aufweist, kann zu 
veränderter biologischer Aktivität und unerwünschten Nebenwirkungen der sEHi führen. Die Tatsache 
dass Leukotoxin-Diol mit der Entstehung von ARDS (Schocklunge) in Verbindung gebracht wird, 
zusammen mit den kinetischen Daten des Leukotoxin-Umsatzes und der Expression von EH3 in der 
Lunge, legen einen Rolle der EH3 in der Entstehung dieses progressiven Lungenversagens nahe. Die 
Entwicklung und Herstellung einer EH3 knock-out Maus wäre von grossem Nutzen um die 
physiologische Rolle von EH3 genauer aufzuklären. Darüber hinaus kann eine genauere Analyse des 
Substratspektrums, sowie nähere Untersuchungen der Expression und Regulation von EH3, zum 
besseren Verständnis von EH3 als physiologischen Regulator beitragen. Dies hilft die Ursachen 
verschiedener Krankheiten besser zu verstehen und ist von Bedeuting für die Entwicklung neuer 
Medikamente. 
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2 INTRODUCTION 
2.1 Epoxide hydrolases  
Epoxide hydrolases (EHs, EC 3.3.2.3) are enzymes that catalyze the hydrolysis of exogenous and 
endogenous epoxides to their corresponding diols by addition of water (figure 2-1). 
 
 
 
 
 
 
 
 
 
 
EHs are ubiquitously found in nature and are present in various organisms including microorganisms, 
plants, insects and mammals. In bacteria, EHs are important for catabolic pathways that enable 
microorganisms to use specific carbon sources as food. One example is the epoxide hydrolase from 
Rhodococcus erythropolis, which catalyzes the hydrolysis of limonene-1,2-epoxide to limonene-1,2-
diol (van der Werf, Overkamp et al. 1998) and enables the bacteria to thrive on limonene as carbon 
source. Like in bacteria, insect EHs are also involved in the catabolism of different compounds. Many 
chemicals produced by plants for defense against arthropodes are detoxified by insect EHs (Mullin 
1988). In addition, by degradation of signaling molecules such as juvenile hormones (JH), epoxide 
hydrolases are involved in the physiological regulation of these hormones (reviewed in (Newman, 
Morisseau et al. 2005). 
Bacterial and insect EHs are key players in degradation of specific carbons, whereas EHs in plants 
play a role in anabolic processes like cutin biosynthesis, which is the formation of the waxy cuticle that 
covers the aerial parts of plants and hence serves as barrier for pathogens (Heredia 2003). EHs are 
found in several higher plants investigated so far (e.g. soybean, tobacco and potato) and are 
moreover important for synthesis of antifungal chemicals that function in pathogen defense (Guo, 
Durner et al. 1998) and stress response (Kiyosue, Beetham et al. 1994). 
Regarding mammalian EHs, five enzymes have been described so far: soluble epoxide hydrolase 
(sEH), microsomal EH (mEH), cholesterol EH (ChEH), hepoxilin hydrolase and leukotriene A4 (LTA4) 
hydrolase (reviewed in (Decker, Arand et al. 2009). Among vertebrates, mEH and sEH are the ones 
best investigated and much is known about their structure, function and physiological relevance. Their 
role in detoxification of exogenous epoxides has been intensely investigated. More recently research 
started focusing on their role in physiological regulation by hydrolysis of endogenous, biologically 
active epoxides (see chapter 2.2.2). Both mEH and sEH show structural characteristics that classify 
them as members of the α/β hydrolase fold superfamily and suggest parentage from a common 
ancestor protein (2.1.1). In contrast, LTA4 hydrolase and most likely ChEH do not belong to the α/β 
hydrolase fold superfamily. 
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Figure 2-1: Enzymatic reaction catalyzed by epoxide hydrolases. Addition of a water 
molecule results in the formation of the corresponding vicinal diol. 
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To date, there is no gene sequence of ChEH known and no data on the characterization of the purified 
enzyme available, although its activity towards cholesterol-5α-6α-epoxide was already described by 
Aringer et al. in 1974 (Aringer and Eneroth 1974). LTA4 hydrolase is an enzyme relevant for immune 
response. It hydrolyzes the arachidonic acid derived Leukotriene A4 to biologically active Leukotriene 
B4 (McGee and Fitzpatrick 1985), that plays a role in adhesion and activation of leukocytes, chemo 
attraction of neutrophils and in ROS generation (reactive oxygen species). The tertiary structure and 
the catalytic mechanism of LTA4 hydrolase is different from that of mEH and sEH, giving the enzyme a 
unique position among EHs. In contrast to the vicinal diols generated by members of the α/β-hydrolase 
fold EHs, LTA4 hydrolase introduces hydroxyl groups located eight carbon atoms apart from each 
other (Arand, Cronin et al. 2003). Mammalian LTA4 hydrolase is, like FosX epoxide hydrolase from 
Mesorhizobium loti, a Zn2+ and Mn2+ dependent metalloenzyme (Haeggstrom, Kull et al. 2002; 
Fillgrove, Pakhomova et al. 2003; Rigsby, Fillgrove et al. 2005). 
The hydrolase activity of hepoxilin epoxide hydrolase against the arachidonic acid derived hepoxilin 
A3 was first demonstrated by Pace-Asciak and colleagues (Pace-Asciak and Lee 1989) who isolated 
and purified the enzyme from rat liver cytosol. However there is reason to believe that the observed 
activity is actually attributable to sEH (oral communication of unpublished data by Dr. Annette Cronin).  
 
2.1.1 The α/β hydrolase fold family 
Most epoxide hydrolases of known sequence are members of the so called α/β hydrolase fold 
superfamily. The α/β hydrolase fold is a very common tertiary fold found in many different proteins of 
which all diverged from a common ancestor. Although these proteins differ in amino acid sequence 
and substrate spectra, all share the same structure and arrangement of the catalytic residues which 
compose the conserved catalytic triad. Examples of α/β hydrolase enzymes besides EHs are lipases, 
esterases (e.g. acetycholine esterase), proteases and dehalogenases. The α/β hydrolase fold, first 
identified by Ollis et al. in 1992 (Ollis, Cheah et al. 1992), is a subclass of α/β proteins that is 
composed of central β-sheets which are mostly arranged in parallel and surrounded by α-helices on 
both sides. mEH and sEH were classified as α/β fold hydrolases due to their structural similarity 
(Arand, Grant et al. 1994; Lacourciere and Armstrong 1994) to haloalkane dehalogenase (Janssen, 
Pries et al. 1989). The typical features of the α/β hydrolase fold domain are illustrated in figure 2-2, 
which depicts the 3D structure of the EH from Agrobacterium radiobacter. It was the first published X-
ray structure of an epoxide hydrolase (Nardini, Ridder et al. 1999) that showed sequence similarity 
with mammalian EHs, in particular with sEH. The 3D structure of the EH of A. radiobacter revealed the 
following conserved structural elements of α/β hydrolase fold EHs (schematic illustration figure 2-3): 
the central core, that consists of eight central β-sheets that are surrounded by α-helices, is covered by 
a variable lid domain inserted between strand 6 and 7. Thereby it provides the epoxide binding pocket 
at the interaction site. The catalytic residues are highly conserved among α/β hydrolase fold EHs: the 
catalytic nucleophile (aspartate) is located after strand β5, the acidic residue (aspartate or glutamate) 
is positioned after β7 and the highly conserved water activating histidine residue is situated after the 
last β strand which takes part in building the charge relay system together with the acidic residue.  
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The αC helix (figure 2-3) plays a key role in positioning of the nucleophilic residue and thus is well 
conserved among α/β hydrolase fold proteins. The aspartate is located in a sharp turn, the so called 
“nucleophilic elbow”, where it can be easily approached by the substrate and the hydrolytic water 
molecule (Nardini and Dijkstra 1999). The nucleophilic elbow is identified by the sequence motif Sm-X-
Nu-X-Sm-Sm (Sm: small residue, X: any residue, Nu: nucleophile) (Arand, Grant et al. 1994). Other 
conserved sequence motives are the oxyanion hole, located between β3 and αC (figure 2-3), and the 
G-X-Sm-X-S/T motif, located between the oxyanion hole and the catalytic nucleophile. While the latter 
is of unknown function, the oxyanion hole (H-G-X-P) stabilizes the negatively charged transition state 
that appears during hydrolysis. Residue X of the H-G-X-P motif, usually an aromatic amino acid, acts 
together with the residue directly following the catalytic nucleophile (van Loo, Kingma et al. 2006) to 
form this stabilizing unit. Two tyrosine residues, which discriminate EHs from other family members, 
are located in the lid domain and position the epoxide within the active site. Apart from the highly 
conserved sequence motifs described above, the amino acid sequence varies highly among the EH 
family. Nevertheless, these motifs can be used to identify putative EHs and distinguish them from 
related α/β-hydrolase fold enzymes like esterases and dehalogenases (see 2.4).  
 
 
Figure 2-2: Schematic view of the secondary structure elements of the epoxide hydrolase 
from Agrobacterium radiobacter. α-helices, β-strands, and coils are represented by helical 
ribbons, arrows, and ropes, respectively. The α-helices of the cap domain are shown in dark 
gray. (Krig, Jin et al. 2007) 
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2.1.2 Mechanism of epoxide hydrolysis 
The sequence similarity of mEH and sEH, to bacterial haloalkane dehalogenase (HAD) led to the 
assumption that the catalytic mechanism of these two EHs is similar to that of the bacterial enzyme 
(Arand, Grant et al. 1994). The catalytic mechanism of HAD was unveiled by Verschueren et al. and is 
characterized by a two step process that involves the formation of a covalent alkyl ester intermediate 
(Verschueren, Seljee et al. 1993). The work of Lacourciere and Armstrong could demonstrate the 
formation of an ester intermediate for mEH by showing that during single turnover experiments the 
oxygen of H218O is incorporated in the protein and not in the corresponding diol (Lacourciere and 
Armstrong 1993), and thus provided evidence for the suggested two step mechanism. Several other 
studies to enlighten the mechanism of epoxide hydrolysis supported the initial hypothesis and helped 
to elucidate the mechanism in detail (figure 2-4) (Arand, Wagner et al. 1996; Muller, Arand et al. 1997; 
Laughlin, Tzeng et al. 1998; Argiriadi, Morisseau et al. 1999; Armstrong and Cassidy 2000; Arand, 
Cronin et al. 2003). 
First, the substrate enters the binding pocket and binds to the active site. The active site is composed 
of the catalytic triad Asp – His – Asp/Glu (figure 2-4). At the same time the hydroxyl groups of two 
tyrosine residues position and polarize the epoxide by forming hydrogen bonds with the epoxide 
oxygen. In the first step, one of the two carbon atoms (usually the more accessible and most reactive 
one) in the epoxide is attacked by the catalytic nucleophile (carboxylic acid of Asp) which leads to 
formation of an ester intermediate. In the second step, the covalent ester – intermediate is hydrolyzed 
by an activated water molecule to release the diol product and the regenerated enzyme. The water 
molecule is activated by proton abstraction through the histidine residue leading to a positive charge in 
the aromatic amino acid. The negatively charged tetrahedral intermediate is compensated by the 
Figure 2-3: Secondary structure of the α/β- hydrolase fold domain. α- helices and β-
barrels are shown as white cylinders and gray arrows, respectively. The catalytic triad is 
indicated by black dots. (picture taken from (Nardini and Dijkstra 1999) 
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backbone amides of the “oxyanion hole” (see 2.1.1) and the acidic aspartate (glutamate residue in 
case of mEH; Verschueren, Seljee et al. 1993). 
All α/β hydrolase fold EHs share this mechanism, which is deduced from the mechanism of bacterial 
haloalkane dehydrogenase (HAD). Before the similarity of these enzymes to HAD was discovered, it 
was generally assumed that the hydrolysis by EHs follows a single step mechanism, like the one used 
by bacterial limonene epoxide hydrolase (LEH) from Rhodococcus erythropolis (Arand, Hallberg et al. 
2003). This mechanism displays a faster epoxide hydrolysis but is associated with a narrow substrate 
spectrum due to the spatial fixation of the catalytic nucleophile. Regarding α/β-hydrolase fold 
enzymes, the catalytic nucleophile is located in a flexible turn (“nucleophilic elbow”) and thus can 
adapt to various spatially different epoxides which has some implications in the detoxification of 
genotoxic epoxides by EHs. 
 
2.2 Function and human relevance of sEH and mEH 
Whereas the functions of EHs in plants and bacteria can be ascribed to host defense, cutin 
biosynthesis and growth, the role of mammalian EHs is at least of dual function. Firstly, EHs play a key 
role in detoxification of a variety of genotoxic epoxides. Secondly, it has recently become evident that 
they are involved in the regulation of certain epoxides that act as physiological signaling molecules 
(figure 2-5). 
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Figure 2-4: Catalytic mechanism of epoxide hydrolysis. The ring opening and formation of the 
covalent ester intermediate is assisted by two tyrosine residues, which position the epoxide in the 
active site. The ester intermediate is then hydrolyzed by an activated water molecule to subsequently 
release the diol and the original enzyme.  
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2.2.1 Epoxide hydrolysis - role in detoxification 
Epoxide hydrolases have first been identified as detoxifying enzymes (Oesch 1973), because many 
epoxides have genotoxic and cytotoxic properties: the high ring tension and the positive charge of the 
carbon atom lead to electrophilic reactivity of these compounds, enabling them to react with 
nucleophilic sites in proteins and nucleic acids. Modification of DNA bases at exocyclic amino groups 
or nitrogen atoms of purin bases leads to misincorporation during DNA replication which can result in 
permanent mutation. Since mutations in protooncogenes or tumor suppressor genes are critical in 
terms of induction of tumor formation, many epoxides are generally regarded as carcinogens. 
Genotoxic epoxides arise during phase I metabolism in the human liver where CYP 450 mediated 
monooxygenation of double bonds in aromatic ring systems and alkenes of xenobiotic compounds 
bioactivate initial harmless substances to genotoxic epoxides. Hence the deactivation and metabolic 
control by epoxide hydrolysis to produce the less reactive and more water soluble diol is an important 
mechanism for defense against carcinogenesis (Arand, Hallberg et al. 2003). 
The microsomal EH is generally regarded as responsible for the detoxification of most genotoxic 
epoxides due to its broad substrate specifity, high expression level in the liver and in other 
metabolizing organs, and its inducibility by foreign compounds like phenobarbitone and N-
acetylaminofluorene (Astrom, Maner et al. 1987; Hassett, Turnblom et al. 1989). Good substrates for 
mEH are lipophilic cis – configurated epoxides such as styrene oxide, cis – stilbene oxide, 
benzo[a]pyrene oxide, carbamazepine-10,11-oxide as well as the endogenous signaling molecule 
11(12) epoxyeicosatrienoic acid (11(12) EET; (Decker, Arand et al. 2009). The turnover and 
metabolism of styrene, the precursor of the widely used plastic polystyrene, is an example for the role 
of mEH in detoxification. The DNA reactive styrene 7, 8-oxide (STO) is the major metabolite formed by 
CYP epoxygenases in the liver (Sumner and Fennell 1994) and is regarded as a potential carcinogen. 
In the liver, STO is rapidly hydrolyzed by mEH to the less toxic phenyl glycol and thus terminates the 
genotoxic potential. A study among plastic workers showed that specific STO biomarkers (DNA and 
albumin adducts, sister chromatid exchange) correlate with STO exposure rather than styrene 
exposure (Rappaport, Yeowell-O'Connell et al. 1996). This means that endogenous STO arising from 
exposure to exogenous styrene is sufficiently detoxified in the liver whereas already low exposure to 
STO shows genotoxic effects, because the compound is not detoxified until it reaches the liver. Work 
from Herrero et al. showed that V79 cells that express mEH are protected against the genotoxic 
effects of STO, whereas the control cells exhibit DNA-strand breaks as a result of STO treatment 
(Herrero, Arand et al. 1997). 
However, some genotoxic substrates cannot be hydrolyzed and detoxified by mEH. The soluble EH 
somewhat complements the substrate spectrum of mEH in that it can convert slim trans 1, 2-
disubstituted or trisubstituted epoxides such as trans-stilbene or trans-ethylstyrene oxide which both 
are not hydrolyzed by mEH (Arand, Cronin et al. 2003). In recent years it became evident that the 
enzyme preferentially acts on lipid epoxides and that its major function is the control of endogenous, 
fatty acid derived signaling molecules and thus takes part in physiological regulation. 
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2.2.2 Epoxide hydrolysis - role in physiology  
Apart from their function in detoxification, EHs also play a role in physiological regulation by hydrolysis 
of endogenous epoxides that serve as signaling molecules. Although sEH was first thought to be 
involved in xenobiotic metabolism like mEH, due to the high expression in liver and kidney and its 
complementing substrate spectrum, it is nowadays regarded as the primary enzyme in the turnover of 
several endogenous epoxides, in particular in the hydrolysis of epoxyeicosatrienoic acids (EETs) to 
their corresponding dihydroxyeicosatrienoic acids (DHETs; see figure 2-5). 
Endogenous epoxides like EETs do have little genotoxic potential due to their low chemical reactivity, 
but they have various biological effects including vasodilation, inflammation, cell proliferation, 
angiogenesis and analgesia, depending on cell and tissue type as well as regioisomer. EETs are 
synthesized from arachidonic acid (AA) by a variety of CYP 450 enzymes, mainly CYPs of the 2C and 
2J subfamilies. According to the different double bonds, four EET regioisomers are produced: 5(6)-
EET, 8(9)-EET, 11(12)-EET and 14(15)-EET, each in two different configurations (R and S 
enantiomers). The hydrolysis of EETs by sEH, with the order of preference 14(15)-EET > 11(12)-EET 
> 8(9)-EET > 5(6)-EET, is regarded as the deactivation step of biological activity. Vasodilation is the 
most extensively studied EET function. One important observation was that EETs function as 
endothelium derived hyperpolarization factors (EDHFs), which leads to vasodilation in small resistance 
vessels and coronary arteries, independent of nitric oxide or prostacycline (Fisslthaler, Popp et al. 
1999). Several in vivo studies with sEH inhibitors and sEH-/- mice indicated that EETs do have an 
effect on blood pressure regulation (Imig, Zhao et al. 2002; Fang 2006; Li, Carroll et al. 2008) and 
inflammation. Anti-inflammatory effects of EETs were shown by Smith et al., where tobacco-smoke 
induced inflammation in rats was attenuated after sEH inhibition (Smith, Pinkerton et al. 2005). 
Moreover there is evidence that EETs also regulate or influence cell proliferation, cell migration and 
angiogenesis (Sun, Sui et al. 2002; Potente, Fisslthaler et al. 2003; Michaelis, Fisslthaler et al. 2005). 
The overall mechanism of autocrine and paracrine EET activity is still not clear and under debate. It is 
supposed that they either bind to putative membrane receptors (GPCRs) on the cell surface, to 
activate intracellular signaling pathways, or directly act on ion channels (KATP, TRPV4, L-type Ca2+), 
fatty acid binding proteins and/or transcription factors like PPARγ; (Widstrom, Norris et al. 2001; Liu, 
Zhang et al. 2005). The different cellular effects of EETs on cellular functions have recently been 
reviewed (Spector and Norris 2007). The role of sEH in EET turnover is generally accepted as the 
main function of this epoxide hydrolase and therefore reduces the implication of this enzyme as 
classical detoxification enzyme. This is supported by the fact that the recently discovered phosphatase 
activity of the N - terminal sEH domain (Cronin, Mowbray et al. 2003) plays a role in turnover of 
endogenous lipid phosphates. 
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Figure 2-5: Hydrolysis of 14(15) EET to the corresponding 14(15) DHET by soluble epoxide 
hydrolase. 
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In addition to EETs, there are other arachidonic and linoleic acid derived lipid mediators, which are 
involved in different physiological processes, and have been shown to be hydrolyzed by sEH. One of 
the first reports of turnover of physiological epoxide was the turnover of leukotoxin (Moghaddam, 
Motoba et al. 1996). Leukotoxin (9(10) EpOME) is synthesized in leukocytes from linoleate (Ozawa, 
Sugiyama et al. 1989) and is associated with acute respiratory distress syndrome (ARDS). ARDS is a 
reaction of the lung to various injuries and is characterized by inflammation of lung parenchyma that 
leads to impaired gas exchange, release of inflammatory mediators and hypoxemia. Leukotoxin was 
originally found in plasma of patients suffering from ARDS after severe burns (Ozawa, Sugiyama et al. 
1989; Hayakawa, Kosaka et al. 1990; Kosaka, Suzuki et al. 1994). It was shown that leukotoxin and its 
derivate isoleukotoxin (12(13) EpOME) are synthesized by cytochrome P450 2C9 epoxygenation 
(Draper and Hammock 2000) from linoleic acid. Investigations in vitro (Moghaddam, Grant et al. 1997; 
Moran, Weise et al. 1997) and in vivo (Zheng, Plopper et al. 2001) showed that not the epoxide of 
linoleic acid but the epoxide hydrolase product leukotoxin-diol (9(10) DiHOME) is actually the more 
cytotoxic reagent. Swiss Webster mice dosed with 300mg/kg leukotoxin diol died from ARDS-like 
respiratory distress, whereas leukotoxin treated mice survived at the same dose. A 100% mortality 
was only observed after higher dosage of leukotoxin (600mg/kg) which indicates, that the leukotoxin 
diol is more toxic in vivo. In line with this is the observation that after treatment with 4-phenylchalcone 
oxide, an inhibitor of sEH, the mortality of leukotoxin treated mice decreased. In contrast, there was no 
protective effect on mortality of mice that received the dihydroxy derivate (Zheng, Plopper et al. 2001). 
Though the biological effects of leukotoxin-diol are known, the mechanism of leukotoxin-diol toxicity is 
not fully elucidated. There are indications that point towards mitochondrial disfunction (Sisemore, 
Zheng et al. 2001) and eNOS/iNOS stimulation (Nakanishi, Ishizaki et al. 2000).  
Although the role of sEH in turnover and bioactivation of leukotoxin has been elucidated several years 
ago, the impact of sEH hydrolysis and regulation of other epoxy lipids still is less investigated and only 
recently started to evolve and gain interest. 
The ethanol amide of arachidonic acid – anandamide – is an endocannabinoid that activates the Gi 
protein coupled cannabinoid receptors CB1 and CB2 (Pacher, Batkai et al. 2006). The work of Snider 
showed that anandamide, similar to arachidonic acid, can be epoxygenated by the CYP450 
monooxygenase CYP2D6 (Snider, Sikora et al. 2008) and that one of the arising epoxides, 5(6)- EET-
EA, also is a CB2 receptor agonist (Snider, Nast et al. 2009). The study demonstrated that 5(6)-EET-
EA binds to CB1 and CB2 receptors expressed in CHO cells, albeit affinity to CB2 is orders of 
magnitudes higher than to CB1. In addition to that, they could demonstrate that incubation of 5(6)- 
EET-EA in mouse brain homogenates led to a decrease of the respective epoxide and to an increase 
in the formation of 5(6)-dihydroxyeicosatrienoic acid ethanol amide (5(6)-DHET-EA) over time. This 
effect was AUDA (12-(3-adamantan-1-yl-ureido) dodecanoic acid) sensitive and hydrolysis was dose - 
dependently inhibited by the inhibitor, suggesting that 5(6) EET-EA is hydrolyzed by sEH in the brain. 
Besides epoxidation of arachidonic acid, linoleic acid and anandamide, epoxidation of polyunsaturated 
long chain fatty acids (PUFA) like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has 
been demonstrated. The polyunsaturated ω-3 fatty acid EPA is a substrate for human CYP1A1 
(Schwarz, Kisselev et al. 2004). One major epoxy metabolite, 17(18) EETeE (epoxyeicosatetraenoic 
acid), induces relaxing effects on human pulmonary artery and airway smooth muscles (bronchi) in a 
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concentration dependent manner (Morin, Sirois et al. 2009). The effect can be reversed by addition of 
inhibitors targeting BK-type calcium activated potassium ion channels. This study confirms the finding 
of Lauterbach et al. (Lauterbach, Barbosa-Sicard et al. 2002), who showed a BK potassium channel - 
dependent, 14fold increase of K+ current with 17(R),18(S) EETeE compared to a 6fold increase by 
equimolar concentration of 11(12) EET in rat cerebral vascular smooth muscle cells (VSMC).  
Currently there is no data on specific CYP450 epoxygenation of DHA available. However, hepatic and 
renal microsomes react with DHA to produce the respective epoxy metabolites (VanRollins, Baker et 
al. 1984). Chemically synthesized DHA epoxides (e.g. 19(20) epoxydocosapentaenoic acid; 19(20) 
EDPE) inhibit platelet aggregation and have vasodilative effects on porcine arterioles (VanRollins 
1995; Ye, Zhang et al. 2002) which points towards possible physiological relevance of these 
compounds.  
Both fatty acids, DHA and EPA, are components of fish oil and some of the cardio protective and 
antihypertensive effects described for fish oil diet might be attributed to epoxy derivatives of these 
molecules and their effects on platelet aggregation and vasodilation. 
Hepoxilins (Hepoxilin A3 (HxA3) and B3 (HxB3)) are hydroxyl-epoxy metabolites of arachidonic acid 
and are formed by the 12-lipoxygenase (12S-LOX) pathway (Nigam, Zafiriou et al. 2007) from 
arachidonic acid. Their intrinsic biologic activity relates to inflammation, insulin secretion and 
intracellular Ca2+ release as well as Ca2+ transport. HxA3 plays an important role in the regulation of 
neutrophil migration in inflammatory processes (Mrsny, Gewirtz et al. 2004) and is thought to have 
proinflammatory effects in the skin (Anton, Puig et al. 1998). Together with the fact that mutations in 
the lipoxygenase pathway are associated with ichthyiosis, this indicates that hepoxilins may play a role 
in epidermal differentiation and skin barrier function. Hydrolysis and degradation of hepoxilins to their 
corresponding trioxilins has been reported to be catalyzed by hepoxilin epoxide hydrolase, first 
described two decades ago (Pace-Asciak and Lee 1989). Nevertheless, there is evidence that sEH is 
the actual enzyme relevant for hepoxilin hydrolysis, since kinetic studies on hepoxilin turnover by sEH 
point towards higher turnover and catalytic efficacy compared to the published data from Pace-Asciak 
(unpublished work from Dr. Annette Cronin). 
 
2.3 sEH as pharmacological target - development of sEHi 
Due to the important role of sEH in EET regulation, the enzyme became a potential target for 
treatment of hypertension, inflammatory diseases, pain, diabetes and stroke. The challenge was to 
develop potent sEH inhibitors (sEHi) that were active in vivo and which could be used to investigate 
the physiological roles of EETs as well as to clarify the role of sEH in the metabolism of these 
biologically active epoxides. In addition to that, sEHi are developed to yield drugs that can be used as 
therapeutic in humans and exploit the beneficial effects of EETs as described above. 
Chalcone oxides (Mullin and Hammock 1982) and phenylglycidols (Dietze, Kuwano et al. 1991) were 
the first selective sEH inhibitors. These epoxide containing compounds act as alternative substrates 
that are slowly converted by the epoxide hydrolase and thus only transiently inhibit the enzyme 
(Morisseau, Du et al. 1998). Those compounds were not useful for in vivo application due to the 
reversibility of inhibition and to the fact that these compounds are unstable and inactivated rapidly by 
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glutathione and glutathione transferases (Mullin and Hammock 1982). Morriseau and his colleagues 
discovered substituted ureas and carbamates as more stable and very potent inhibitors of sEH 
(Morisseau, Goodrow et al. 1999). They permanently inhibit sEH activity with nanomolar Ki by imitating 
features of the covalent intermediate transition state. The more effective urea pharmacophore 
interacts with the active site by hydrogen bonds and salt bridges. This was demonstrated by x-ray 
crystallography studies on mouse sEH complexed with disubstituted urea derived inhibitors (Argiriadi, 
Morisseau et al. 2000). 
Altogether, these urea based inhibitors were more useful for in vitro experiments to investigate the 
endogenous role of sEH, but still less applicable for in vivo studies due to the limited water solubility. 
Yet, the in vivo effect was demonstrated by studies in animal hypertension models with DCU (N,N-
dicyclohexylurea) (Yu, Xu et al. 2000) and CDU (1-cyclohexyl-3-dodecyl-urea) (Imig, Zhao et al. 2002), 
where single and chronic administration of sEHi led to lowered blood pressure. To enhance water 
solubility, functional polar groups were integrated into the alkyl side chain of 1,3-disubstitued ureas, 
which resulted in compounds that were weak mimics of EETs but maintained their potency 
(Morisseau, Goodrow et al. 2002; Kim, Heirtzler et al. 2005). One of these inhibitors, 12-(3-
adamantan-1-yl-ureido) dodecanoic acid (AUDA), showed improved physicochemical properties and 
inhibited sEH in both cultured cells and animals (Dorrance, Rupp et al. 2005; Jung, Brandes et al. 
2005; Sellers, Sun et al. 2005; Li, Carroll et al. 2008). Although AUDA can be administered orally and 
is a potent inhibitor, ongoing developments targeted to further increase the bioavailability of this sEHi 
by incorporation of secondary pharmacophores, resulted in the production of t-AUCB (Hwang, Tsai et 
al. 2007). This compound has high bioavailability and potency. Beside the effort to improve sEHi for 
experimental use, the development of compounds for application and therapeutic use in humans has 
progressed. Currently a sEHi is tested in Phase II clinical trial for the treatment of hypertension and 
diabetes (Arete Therapeutics Inc 2009). 
 
2.4 Identification of novel epoxide hydrolases 
The fact that mEH and sEH do have human relevance in terms of detoxification and physiological 
regulation, and even became a pharmaceutical target, raises the question if there are other hitherto 
unknown epoxide hydrolases with similar properties. Such enzymes would open up novel regulatory 
pathways and therapeutic targets or could reveal protective mechanisms towards xenobiotic 
carcinogens. Since the sequence motives of α/β-hydrolase fold enzymes are highly conserved, they 
can be used to identify putative novel epoxide hydrolases. Previous sequence comparisons (Arand, 
Grant et al. 1994) showed that the amino acid sequence RVIAPDLRGYGDSDKP can be used as bait 
in database searches for novel epoxide hydrolase candidates. 
The search motif is sufficient in length and degree of conservation and contains the G-X-Sm-X-S/T 
sequence motif (RVIAPDLRGYGDSDKP) as described in chapter 2.1.1. By searching the genome 
based human protein database with this 16 amino acid query 
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/ BlastGen.cgi?taxid=9606), three novel putative 
EHs were identified in our group: EH3 (ABHD9), EH4 (ABDH7) and peg1/MEST (figure 2-7). 
Sequence alignment of EH3 and EH4 with other mammalian EHs showed that they are related to sEH, 
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and similarity was seen after alignment with two recently identified epoxide hydrolases of C. elegans 
(Harris, Aronov et al. 2008). Figure 2-7 shows the overall relationship of the novel candidate enzymes 
EH3 and EH4 with other known epoxide hydrolases. Further it depicts that EH3 and EH4 represent a 
new subfamily of mammalian EHs due to their 45% sequence identity. Direct sequence analysis and 
comparison with sEH shows that EH3 and EH4 share all characteristic sequence motifs of α/β- 
hydrolase fold EHs that are necessary for epoxide hydrolase function (figure 2-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ceeh2
ceeh1
EH3 (EPHX3/ABHD9)
EH4 (EPHX4/ABHD7)
sEH (EPHX2)
peg1/MEST
mEH (EPHX1)
ceeh3 (EPHX1)
47
45
40
33.0 ± 2.6
23.6 ± 2.4
16.4 ± 0.8
14.5 ± 1.4
α/β hydrolase fold
Figure 2-6: Relationship tree of known and putative mammalian epoxide hydrolases and epoxide 
hydrolases of C. elegans (ceeh). EH3 and EH4 represent a novel subfamily of mammalian 
epoxide hydrolases (mammalian EHs are highlighted in grey). 
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Figure 2-7: Sequence alignment of candidate enzymes EH3 and EH4 with human soluble epoxide 
hydrolase. The characteristic and highly conserved sequence motives for α/β-hydrolase fold EHs are 
indicated. 
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3 AIM OF THE STUDY 
The aim of this work was to biochemically and functionally characterize the putative new human 
epoxide hydrolases EH3 (ABHD7) and EH4 (ABHD7), in order to gather insight into their potential 
toxicological and/or physiological relevance for the human organism. Since there is no data on EH4 
activity available to date, the main objective is to investigate whether EH4 is an enzymatically active 
epoxide hydrolase. The characterization of EH4 comprises two approaches: 
a) the recombinant expression of enzymatically active EH4 protein in order to investigate the 
enzymatic activity towards different epoxides, 
b) the generation of a detection tool that would allow the detection of EH4 in recombinant lysates and 
different tissues. 
Previous work in our group demonstrated that EH3 has epoxide hydrolase activity. Epoxide hydrolases 
fulfill two different functions for the human organism. Depending on the substrate spectrum, they either 
play a role in the detoxification of genotoxic epoxides, or in the turnover of endogenous signaling 
molecules. This raises the question if EH3 is a detoxifying enzyme or a physiological regulator. To 
answer this question, the respective substrate spectrum of EH3 should be analyzed. The 
characteristics of the substrate spectrum could give information on the preferred substrates of EH3 
and therefore on the relevance of the novel epoxide hydrolase for the human organism. 
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4 MATERIALS AND METHODS 
4.1 Chemicals and enzymes 
All chemicals were obtained from Roth (Roth AG, Arlesheim, Switzerland) and Sigma (Sigma-Aldrich, 
Basel, Switzerland) if not indicated otherwise. Restriction endonucleases were derived from NEB (New 
England BioLabs). Fatty acid derived epoxy substrates were purchased at CaymanChemicals, EETs 
and DHETs were kindly provided by Dr. John Falck (University of Texas). Taq Polymerase and Pfu 
Polymerase were kindly provided by Dr. Annette Cronin (University of Zurich, Switzerland). 
 
4.2 Vectors and plasmids 
The IRAK plasmid containing the EH4 cDNA (clone library NIH_MCG_121 ;(Gerhard, Wagner et al. 
2004)) was derived from imaGens (Berlin, Germany). The expression plasmids pRSET b, c and 
pFastBac™ were obtained from Invitrogen (Invitrogen™, Switzerland) and pIRESneo was purchased 
from Clonetech (Clonetech, Europe). The vector named pGEFGSTN was constructed by Dr. Annette 
Cronin via subcloning of the GST gene from the pGEX vector system (Amersham) into pGEF II 
(Arand, Hemmer et al. 1999) by using BspHI and NcoI restriction sites present in the applied primers 
(GST-Sf 5`- cat gtc atg acc cct ata cta ggt tat tgg aaa-3` and GST-Sr 5`- cat gcc atg gcg ctt cca cgc 
gga acc aga tcc ga-3`). Insertion of a His-cassette into pGEF II by the use of the following cassette 
primers resulted in the vector labeled pGEF-HisC (kindly provided by Dr. Annette Cronin): His 
pFastBac for 5’-g cat cac cat cac cat cac ta-3’ and His pFastBac rev 3’-acgtc gta gtg gta gtg gta gtg 
attcga-5’ . Expression vector pGEFHisCnEH2 and EH3 baculovirus originated from previous work of 
Dr. Magdalena Adamska. 
 
4.3 Basic molecular biology methods 
This chapter briefly describes the standard methods used for cloning and generating the respective 
expression constructs used in this work. 
 
4.3.1 PCR 
A specific nucleotide sequence (up to ~10kb) is generally amplified by using PCR technique. 
Amplification of DNA was typically carried out in a volume of 50µl PCR mix containing 250µM dNTPs 
(Fermentas), PCR buffer (10x PCR buffer: 200 mM Tris HCl,100 mM (NH4)2 SO4, 100 mM KCl, 20 mM 
MgSO4, 1% Triton X-100, 1mg/ml BSA, Tris pH 8.8), 25 pmol sense- and antisense-primer, 1µl Taq or 
Pfu Polymerase and 50-100 ng template (for cloning purposes) on a thermal cycler (TGradient, 
Biometra®).  
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4.3.2 TOPO cloning 
Zero Blunt® TOPO® PCR Cloning Kit for Sequencing (Invitrogen) is used for direct insertion of blunt 
end PCR products into a plasmid vector (pCR4Blunt-TOPO®).The resulting plasmid can be analyzed 
by sequencing and/or control digestion to confirm the sequence of the cDNA of interest. The reaction 
was set up according to the manufacturer’s protocol. In brief: 2 - 2.5 µl purified PCR product was 
added to the TOPO® cloning reaction mix. The reaction was incubated 3h at RT before transforming 
(see 4.3.3.) the TOPO-construct into electrocompetent E. coli (Top10). The transformed E. coli cells 
were plated on either ampicillin (100 µg/ml) or kanamycin (50 µg/ml) selective agar plates and 
incubated over night at 37°C. 
 
4.3.3 Transformation and plasmid amplification  
To amplify a particular plasmid or construct, the DNA was transformed into electrocompetent Top10 
(genotype: F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74 recA1 araD139 ∆(araleu) 7697 
galU galK rpsL (StrR) endA1 nupG). Typically 1-3 µl of the respective plasmid or ligation mix was 
added to 40 µl electrocompetent cells and incubated on ice for 5 min, before the cells were 
electroporated at 1.35 kV and 25 µF (BioRad Gene Pulser® Cuvette, 0.1cm electrode; BioRad Gene 
Pulser™). Subsequently 500 µl LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl ) was added 
and cells were incubated (37 °C, 220 rpm) for 45 mi n to allow the expression of the respective 
antibiotic resistance gene(s). 100 µl of the suspension was plated on selective agar plates (3% agar 
(Applichem, Germany) in LB medium) and incubated ON at 37°C in an incubator (HERAEUS). 1-50 ml 
LB medium (100 µg/ml ampicillin) was inoculated with selected colonies the following day and cultured 
ON (37°C, 220 rpm) for amplification of the plasmid . 
 
4.3.4 Plasmid isolation 
In terms of further processing and analyzing the plasmid and its sequence, the plasmid was isolated 
using the HiSpeed® Plasmid Midi Kit (50-150 ml overnight E. coli culture) or QIAPREP® Spin 
Miniprep Kit (1-5 ml overnight E. coli culture) (QIAGEN, Switzerland). Bacterial cells were harvested, 
centrifuged (4.000 rpm, 15 min) and plasmid was isolated according to the suppliers manual. For 
stable transfection into mammalian cells and insect cells, the plasmid /DNA elution was performed 
under sterile conditions. 
 
4.3.5 Analyzing plasmid 
Plasmid was analyzed for correct insert first by appropriate control digestion and subsequent agarose 
gel electrophoresis. The plasmid was incubated with restriction endonucleases and the recommended 
NEB buffer for 1h at the appropriate temperature and then analyzed by 1 - 2% agarose gel 
electrophoresis. To further confirm the nucleotide sequence of the inserted cDNA, the plasmid was 
sent for sequencing (Microsynth AG, Balgach, Switzerland).  
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4.3.6 Cloning of cDNA into target vector 
To clone the cDNA of interest into the respective expression vector, the cDNA containing plasmid 
(TOPO vector or any other plasmid) and the target vector were digested with the respective restriction 
enzymes (1h, 37°C, recommended NEBbuffer). The targ et vector was subsequently dephosphorylated 
for 30 min at 37°C by alkaline phosphatase to preve nt self ligation of the vector. DNA was separated 
electrophoretically and isolated using QIAquick Gel Extraction Kit (QIAGEN, Switzerland). The 
linearized dephosphorylated vector and the respective cDNA fragment was ligated to construct the 
expression vector (Ligase mix (10µl) contains: 2µl 5x Ligase buffer (Invitrogen), 1µl T4 Ligase 
(Invitrogen), 20-50ng vector, 30-100 ng insert). 
 
4.4 mRNA isolation 
For in vitro and in vivo expression analysis by reverse transcriptase PCR (RT-PCR) total mRNA was 
isolated from cultured cells or animal tissues using the Qiagen RNeasy Mini Kit (QIAGEN, 
Switzerland). Cells and animal tissue were first frozen in liquid nitrogen and then mechanically 
disrupted using mortar and pestle. All steps were carried out under RNase free conditions on ice until 
addition of RLT buffer. The subsequent isolation and purification procedure was conducted according 
to the provided manual. 
 
4.5 cDNA synthesis 
The First Strand cDNA Synthesis Kit (Fermentas) was used for the synthesis of first strand cDNA from 
mRNA templates. cDNA was generated using random hexamer primers (supplied by the kit) according 
to the manufacturers manual. The resulting cDNA was directly analyzed by PCR for presence of the 
target transcript using sequence specific primers (PCR conditions and primer sequences see 
appendix). Amplificates were sent for sequencing (Microsynth, Balgach, Switzerland) to confirm 
expression of the respective gene. 
 
4.6 Recombinant protein expression 
4.6.1 Recombinant expression in E. coli 
For recombinant expression in E. coli, the respective expression plasmids were transformed (see 
4.3.3) into arabinose inducible E. coli BL21AI (Genotype: F- ompT hsdSB (rB- mB-) gal dcm 
araB::T7RNAP-tetA). The strain contains the T7 RNAP gene (RNA polymerase) inserted behind the 
araBAD promoter that allows the regulation of expression by arabinose in the medium. Expression 
was induced with arabinose at different concentrations (20 µM - 100 µM) and protein was expressed 
at various temperatures (18°C - 37°C, 220 rpm) for a given time period (4 - 12 h). E. coli cells were 
then harvested and centrifuged (15 min, 4.000 rpm, Megafuge 1.0R), resuspended in the designated 
buffer and disrupted by using a French® Pressure Cell Press (SIM Aminco, Spectronic Instruments; 
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(Vanderheiden, Fairchild et al. 1970)). Soluble and insoluble protein fractions were analyzed by SDS 
Page and western blot as described in chapter 4.7. 
 
4.6.2 Recombinant expression in mammalian cells 
For recombinant protein expression in mammalian cells, stable transfectants of Cos-7 (african green 
monkey kidney) (Gluzman 1981) and V79 (chinese hamster lung fibroblasts) (Ford and Yerganian 
1958) cells were established and analyzed.  
4.6.2.1 Cultivation of mammalian cells 
Cos-7 and V79 cells were cultivated in DMEM medium (Gibco) supplemented with 10% FCS and 2mM 
Glutamine at 37 °C with 5% CO 2 (Forma Scientific). Cells were grown until they reached confluency 
and split 1:5 to 1:10 every 2-3 days by using 0.25% Trypsin/EDTA (Gibco). 
 
4.6.2.2 Stable transfection 
For stable transfection Cos-7 cells were seeded in 6 well/plate at 1.5 x 105 and V79 cells at 2.5 x 105 
cells/well and cultured ON to reach 50-60% confluency. To introduce DNA into the cells the jetPEI™ 
DNA transfection reagent (POLYPLUS-TRANSFECTION, Illkirch Cedex, France) was used according 
to the manufacturers instruction. In brief: 2- 4 µg of DNA and 5 µl jetPEI™ transfection reagent were 
diluted in 150 mM NaCl (sterile) to a final volume of 100 µl. To form the DNA/jetPEI™ complex, the 
jetPEI solution was added to the DNA solution and the mix was then incubated for 15-30 min at RT 
prior to addition of the mix into the medium. The control well was treated with the NaCl / jetPEI™ mix, 
to test for cytotoxicity of the transfection reagent and/or the recombinantly expressed protein. Stable 
transfected cell lines were obtained by G418 selection (500 µg/ml) during 1 month of cell culturing as 
follows: transfected cells were seeded in 10 cm dishes and cultivated in selective medium until single 
clones were visible. Clones were then isolated, transferred into a 12-well plate and cultivated. Cells 
were analyzed for expression of recombinant protein by RT-PCR. 
 
4.6.3 Recombinant expression in insect cells 
For recombinant protein expression in insect cells the baculovirus expression vector system (BEVS, 
Invitrogen) was used. To express heterologous proteins, insect cells are infected with a recombinant 
baculovirus. The gene that encodes for the matrix protein polyhedrin of the wild-type baculovirus is 
replaced with the recombinant gene and hence controlled by a baculovirus specific promoter. After 
infection of the host cells, these cells express the recombinant protein at the very late state of infection 
(4-5 days post infection) and the protein is generally processed, modified and targeted to the 
respective cellular location. 
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4.6.3.1 Generation of Bacmid 
For the production of the recombinant baculovirus, a baculovirus shuttle vector (Bacmid) containing 
the gene of interest was generated by using the Bac-to-Bac® Baculovirus Expression System 
(Invitrogen). This system is based on site specific 
transposition of an expression cassette that is located on a 
donor plasmid, into the baculovirus genome (present as large 
bacmid in specifically engineered E. coli cells). The 
transposition into the bacmid proceeds in modified E. coli cells 
(DH10Bac™) by taking advantage of the bacterial Tn7 
transposon (Luckow, Lee et al. 1993). First, the gene of 
interest is cloned into the pFastBac™ donor plasmid to 
generate a recombinant donor plasmid (figure 4-1). The 
expression cassette of the donor plasmid is flanked by the two 
transposase binding sites Tn7R and Tn7L respectively and 
controlled by the Autographa californica multiple nuclear 
polyhedrosis virus (AcMPNV) polyhedrin (PH) promoter 
(pPolh). The recombinant donor plasmid is then transformed into chemically competent DH10Bac™ E. 
coli cells to form the recombinant baculovirus (figure 4-3). DH10Bac™ cells contain a baculovirus 
shuttle vector (Bacmid) that replicates in E. coli like a large plasmid and yields infectious virus particles 
when introduced into insect cells. Besides the 
recombinant bacmid that contains a mini attTn7 target 
site, DH10Bac™ cells include a helper plasmid which 
provides Tn7 transposase (figure 4-2). The transposase 
encoded on the helper plasmid binds to the transposase 
binding sites Tn7R and Tn7L on the donor plasmid and 
leads to transposition of the expression cassette into the 
mini attTn7 target site within the bacmid. Since all three 
plasmids display different antibiotic resistance genes and 
insertion into the mini attTn7 site disrupts LacZα reading 
frame, positive recombinant bacmids can be indentified by using selective conditions and blue/white 
screening (Ullmann, Jacob et al. 1967). Positive bacterial clones are inoculated into LB medium 
(kanamycin 50 µg/ml, gentamycin 7 µg/ml, tetracycline 10 
µg/ml) and cultured ON (37°C, 220 rpm). The Bacmid 
was isolated as described in 4.3.4. (For subsequent 
transfection of the bacmid into insect cells, elution of the 
bacmid DNA from the DH10Bac™ cells needs to be 
performed under sterile conditions). 
 
 
Figure 4-1: Generating a 
recombinant donor plasmid 
Figure 4-2: Transposition of expression 
cassette into Bacmid in DH10Bac™ 
Figure 4-3: Recombinant Bacmid 
containing the foreign gene 
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4.6.3.2 Transfection of insect (Sf9) cells  
The Sf9 cell line used in this study derives from clonal isolation of the Spodoptera frugiperda cell line 
IPLB-Sf21-AET, which was originally isolated from ovarian tissue of the fall armyworm (Vaughn, 
Goodwin et al. 1977). For introducing the recombinant bacmid DNA into the cells, the jetPEI™ DNA 
transfection reagent (POLYPLUS-TRANSFECTION, Illkirch Cedex, France) was used as described in 
4.6.2.2. For transfection of Sf9 cells, 4x105 cells/well were seeded in a 6-well plate and cultured ON in 
TMN-FH Insect Medium (BD Bioscience, Belgium) to form a monolayer culture. After transfection with 
the bacmid DNA, the plate was incubated at 28°C (He raeus) for 3-4 days until signs of infection 
(compared to control plate) were visible. The Virus was harvested by collecting the medium and used 
as virus stock (labeled P0). Then immediately 200 µl lysis buffer (10 mM Tris, pH 7.5; 130 mM NaCl; 
1% Triton™-X-100; 10 mM NaF, 10 mM NaPi, 10 mM NaPPi) was added to the well, cells were 
scraped and transferred to a 1.5 ml tube (Eppendorf). The sample was incubated on ice for 45 min 
and then homogenized by passing the lysate 3 times through a 27G syringe. Subsequent analysis for 
recombinant protein expression by western blot was performed as described in 4.7.3. 
 
4.6.3.3 Routine cultivation and expression of recombinant protein 
Sf9 cells were generally sub cultured as monolayer in a 75 cm2 flask (28°C, TMN-FH Insect Medium) 
and split 1:20 when they reached 80 - 100% confluency. For recombinant expression of proteins, Sf9 
cells were cultured in suspension (RT, 100 rpm). Insect cells can adapt from monolayer to suspension 
culture conditions because the cells are not anchorage dependent per se. Typically 25-100 ml SF-3 
BaculoExpress ICM medium (Amimed®, Switzerland) was inoculated with cells to reach a density of 
0.5 - 1x106 cells/ml and cells were infected when they reach a density of 2x106 cells/ml. Virus titer was 
determined by EPDA (End-point dilution assay) and Plaque assay as described in the Baculovirus 
Expression Vector System Manual (Pharmingen 1999). Cells were infected with a MOI (multiplicity of 
infection) between 1 and 5 and incubated (RT, 100 rpm) for 4 -6 days. Cells were harvested, washed 
with assay buffer (10mM Tris, 1mM EDTA, 100mM NaCl, 6% Glycerol, pH7.4) and disrupted by 
French® pressure cell press. Aliquots were frozen in liquid nitrogen and stored at -80°C for up to 6 
months. 
 
4.7 Protein analysis and characterization 
4.7.1 SDS-PAGE 
Separation of proteins was done by either Tris-Glycine (Laemmli 1970) or Tris-Tricine SDS- PAGE 
(Schagger and von Jagow 1987) according to the molecular size of the target protein. Tricine SDS-
PAGE is the preferred method for separating molecules smaller than 30kDa. 
Proteins are concentrated in the stacking gel (pH 6.8) and separated due to molecular weight in the 
running gel (pH 8.8). The composition of the running and stacking gels are shown below (tables 4-1 
and 4-2). Samples were mixed with laemmli buffer (15% SDS, 10% Glycerol, β-Mercaptoethanol 1:10 
(added before use)) and incubated at RT for 10 min or at 60°C for 5 min since EH3 turned out to be 
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heat sensitive during the present work. Tris-Glycine electrophoresis was performed in polyacrylamide 
running buffer (1x PAA buffer: 25 mM TrisBase, pH 8.3, 250 mM Glycine, 0.1% SDS). The Tris Tricine 
buffer system consists of two different buffers: anode buffer (0.2M Tris, pH 8.9) and cathode buffer 
(0.1M Tris, 0.1M Tricine, 0.1%SDS, pH 8.25) which were added separately to the lower electrode 
(anode buffer) and upper electrode (cathode buffer) respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tris Tricine SDS PAGE 
  
 stacking gel (6%) running gel (16%) 
 [ml] [ml] 
Rotiphorese® Gel 30 7.2 33.6 
Gel buffer (3M Tris, 0.3% SDS) 4.5 21 
Glycerol (99.5%) - 8.19 
H2O 24.3 0.21 
10% APS 0.3 0.214 
TEMED 0.03 0.021 
Table 4-2: Composition of PAA gels for Tris-Tricine SDS-PAGE. Volumes given in the table are 
adequate for preparation of 7 gels using (8x9cm). 
 
4.7.2 Coomassie staining 
To visualize the separated proteins in polyacrylamide gels, the respective gels were stained with 
Coomassie (6µM Brilliant Blue R, 6µM Brilliant Blue G, 45% methanol, 10% acidic acid) for 20 
minutes. Unspecific non-protein bound coomassie was destained by incubation in destaining solution 
(10% acetic acid, 15% 2-propanol) for at least 2 hours. 
 
Tris Glycine SDS-Page 
  
 
 
stacking gel (5%) running gel (12.5%) 
 
[ml] [ml] 
Rotiphorese® Gel 30 5.6 29.12 
0.5M Tris, pH 6.8 0.875 - 
1.5M Tris pH 8.8 - 17.5 
H2O bidest 28 21.7 
10% SDS 0.35 0.7 
10% APS 0.35 0.7 
TEMED 0.035 0.07 
Table 4-1: Composition of PAA gels for Tris-Glycine SDS-PAGE. Volumes given in the table 
are adequate for preparation of 7 gels (8x9cm). 
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4.7.3 Western blot analysis 
To detect specific proteins in tissue homogenates of cell lysates, western blot analysis was performed. 
Proteins were blotted onto a PVDF membrane (Immobilion-P, Millipore, USA) using semi dry blotting 
technique. The PVDF membranes for blotting were first activated in methanol and subsequently 
equilibrated in blotting buffer (10% PAA buffer, 20% methanol) prior to use. The PVDF membrane and 
the PAA gel was placed between two layers of filter membranes (3 filter membranes each, equilibrated 
in blotting buffer). After blotting for 2h at 0.17 mA /cm2 the membrane was blocked in 5% non fat dried 
milk in TBST (10 mM Tris, 150 mM NaCl, 0.5% Tween 20, pH 8.0) for 1h at room temperature on an 
orbital shaker. Incubation with the first antibody (at a dilution of 1:1000 for both α-His and α-EH3) was 
carried out in 5% non fat dried milk in TBST or E. coli lysate (6 mg/ml total protein) for 3h at room 
temperature or ON at 4°C. Membranes were rinsed thr ee times for 5 min in TBST prior to incubation 
with the second antibody. After the incubation with the second AP conjugated antibody (anti rabbit 
IgG, whole molecule, F(ab`)2 fragment, Sigma, 1:10.000) for 1h at room temperature (orbital shaker), 
the membrane was washed twice for 5 min in TBST before equilibrating with AP-buffer (100 mM NaCl, 
100 mM Tris, 5 mM MgCl, pH 9.5) for 5 min. For analysis of protein expression in human tissues a 
total protein western blot of human tissues was purchased from AMS Biotechnology (AMS 
Biotechnology, Europe, Lugano) and analyzed as described above. Protein was visualized using BCIP 
and NBT as colorigenic substrate. 
 
4.7.4 Protein purification 
4.7.4.1 GST affinity chromatography 
For batch purification of GST-tagged proteins the Glutathione sepharose 4B (Amersham) was used. A 
50% GSH sepharose slurry in binding buffer (PBS: 140 mM NaCl, 2.7 mM KCl, 10 mM, Na2HPO4, 1.8 
mM KH2PO4, pH 7.4) was prepared as described in the manufacturers manual. The protein solution 
corresponding to approx. 10 mg GST fusion protein was incubated with GSH sepharose for 1 hour at 
4°C (60rpm). The suspension was then centrifuged (5 min, 500g) to sediment the sepharose and the 
supernatant (unbound proteins) was discarded. The sepharose pellet was then washed three times 
with binding buffer (10 times the bed volume) before incubation with elution buffer (10 mM GSH, 50 
mM Tris, pH 8.0) for 10 minutes at RT and 60 rpm. To collect the eluted proteins the suspension was 
centrifuged (5 min, 500 g) and the supernatant was collected. The elution was repeated twice. The 
different fractions were analyzed by SDS-Page.  
 
4.7.4.2 Affinity chromatography of His-tagged proteins 
Histidine is an amino acid that interacts with immobilized Ni2+ ions by forming coordination bonds 
between the electrons of the imidazole ring and the metal ion. Proteins or peptides that contain a 
sequence of histidine residues are retained on a Ni2+ affinity matrix and may be eluted by adding free 
imidazole. Sf9 cells (1.8x108 in 35 ml PBS; MOI 5, dpi 8) recombinantly expressing His-tagged protein 
were resuspended in start buffer (500mM NaCl, 20% glycerol, 20mM sodium phosphate, pH 7.5) and 
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disrupted by French® pressure cell press. Cell lysates were centrifuged (45 min, 14.000 rpm) and the 
sterile filtered supernatant was injected on the column. Samples were separated on a HiTrap 
Chelating HP column (1 ml, Amersham Biosciences) using a Biologic DuoFlow system from BioRad. 
The mobile phase consisted of (A) 500mM NaCl, 20% glycerol, 20mM sodium phosphate, pH 7.5 and 
(B) 500mM imidazole, 500mM NaCl, 20% glycerol, 20mM sodium phosphate, pH 7.5 at a flow rate of 
1ml/min. Starting conditions (97% A, 3% B) were maintained for 5 minutes before injection of 40 ml 
sample for 40 min, followed by isocratic flow (97% A, 3% B) for 7minutes to load the total sample 
volume on the column. A 2-step linear gradient was applied as follows: from 3% to 20% B within 8 
minutes followed by increasing buffer B from 20% to 100% within 8 minutes. An isocratic flow of 100% 
B was held for 2 minutes before conditions were reset to starting conditions (97% A, 3% B within 2 
minutes) and maintained for 5 minutes.  
His-tagged proteins expressed in E. coli were resuspended in ib buffer (6M Urea, 100mM Tris, NaN3, 
pH 8.5) to resolve inclusion bodies prior to purification.  
 
4.7.5 Peptide Analysis by LC-MS/MS 
LC-MS/MS is commonly used in proteomics to identify proteins from complex mixtures (e.g. blood 
samples, cell lysate) or to investigate specific posttranslational modifications of a target protein. 
Protein samples are first digested enzymatically before separation and analysis by liquid 
chromatography and mass spectrometry. The resulting MS data are used to identify proteins from 
primary sequence databases using the Mascot search engine. 
In this work LC-MS/MS analysis was used to confirm the presence of proteins in whole Sf9 cell 
lysates. 
 
4.7.5.1 Sample preparation from Sf9 culture (methanol extraction) 
Sf9 cells were cultured in monolayer (6-well plate) and infected with a recombinant baculovirus for 
expression of foreign protein. 4 days after infection cells were harvested by scraping and sonified 
(Sonorex, Bandelin) before centrifugation at 14.000 rpm for 10 minutes (Centrifuge 5417R, 
eppendorf). The isolation of membrane proteins and sample preparation for LC-MS/MS analysis was 
performed according to the protocol of Blonder and colleagues (Blonder, Chan et al. 2006). 
Solubilisation buffer (60% methanol, 100mM NH4HCO3, pH 7.8) was added to the pellet to reach a 
final concentration of approximately 1µg/µl membrane proteins (based on the assumption that 7% of 
total pellet cell mass refer to total protein content of which approximately 10% are membrane proteins. 
The density of the pellet is estimated to 1g/ml). The pellet was solubilized by 10 cycles of sonification 
for 1 minute and vortexed for 2 minutes prior to protein denaturation for 1min at 90°C. After 
denaturation of the proteins the sample was immediately incubated on ice until further processing. 
Proteins were digested by adding trypsin directly into the solubilising buffer (with a trypsin/protein ratio 
of 1/50). Samples were incubated at 37°C for 5h bef ore the digest was centrifuged for 3 min at 14.000 
rpm. The collected supernatant was lyophilized under a stream of nitrogen, resolved in 100 µl 10% 
acetonitrile in 0.1% formic acid and analyzed by LC-MS/MS. 
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4.7.5.2 Sample preparation from coomassie gel (in gel digestion) 
Proteins of Sf9 lysates were separated on a 12.5 % SDS gel and stained with coomassie blue for 
visualization. The protein of interest was excised from the gel and cut in 1 mm3 pieces. To destain and 
shrink the gel pieces, samples were incubated twice with 50% acetonitrile in 20 mM NH4CO3 buffer 
for 30 min at 37°C, before gel pieces were dried un der vacuum and proteins were digested with 5 
ng/ml trypsin in 100 µl digestion buffer (10 mM NH4CO3, 10% acetonitrile, 0.01% Triton X-100, pH 
8.0) ON at 37°C. After sonification for 5 min the s upernatant was collected, dried under a stream of 
nitrogen and the peptides were resolved in 2% acetonitrile in 0.1% formic acid. Before LC-MS/MS 
analysis, the sample was filtered through 0.45 µm regenerated cellulose filter (infochroma AG, Zug, 
Switzerland). 
 
4.7.5.3 LC-MS/MS measurement 
The resulting peptides were separated on a Agilent 1100 liquid chromatography system using a 
Agilent ZORBAX 300SB-C18 narrow bore reversed phase column (2.1 µm x 150 mm, pore size 5 µm) 
connected to the corresponding ZORBAX 300 SB guard column. The mobile phase includes (A) 0.1% 
formic acid and (B) acetonitrile containing 0.1% formic acid, using a flow rate of 170 µl/min and an 
injection volume of 5 µl. Starting conditions of 2% buffer B were maintained for 5 min, followed by a 
linear gradient from 2% to 100% B within 50 min. An isocratic flow of 100% buffer B was applied for 
5 min, and finally the column was re-equilibrated for 10 min with 2% buffer B. The HPLC system was 
coupled to a 4000 QTrap hybrid quadrupole linear ion trap mass spectrometer (Applied Biosystems) 
equipped with a TurboV source and ESI interface. For the selective identification of EH4 peptides, the 
QTrap system was configured to detect specific transitions in a MIDAS workflow using MRM in the 
positive mode with the following source-specific parameters: IS = 5000 V, TEM = 450 °C, curtain 
gas = 25 (CUR), nebulizer gas = 40 (GS1), heater gas = 50 (GS2) and collision gas = 10 (CAD). For 
detection of EH4 peptides, a list of MRM transitions was generated either by manual calculation or by 
the Applied Biosystems MIDAS software (see appendix for details). Transitions were included for 
tryptic peptides (maximum of one missed cleavage) for single- to triple-charged species for the Q1 
mass range 400–2000 m/z using calculated collision energies and a dwell time of 14 ms for each 
MRM transition to ensure analysis during the peak elution time. In the triple-quadrupole scan function, 
the precursor ions were selected by the first quadrupole set with a unit mass window. Using an 
information-dependent acquisition (IDA) workflow, the mass spectrometer was switched to an 
enhanced product ion scan mode, when an individual MRM signal exceeded 200 counts. All MRM 
transitions were measured sequentially with the cycle time of 3.22 s looped throughout the length of 
the HPLC separation. Enhanced product ion scanning was carried out using parameters detailed in 
the appendix (8.6.4). Fragment spectra were matched against a protein sequence database (National 
Center for Biotechnology Information) using the Mascot search engine (Matrix Science Ltd.). All 
Mascot searches were performed species specific, with trypsin plus one missed cleavage, a peptide 
tolerance of 1.2 Da, and an MS/MS tolerance of 0.5 Da, allowing error-tolerant searches. In addition, 
data were examined manually using the features of the Analyst 1.4.2 software package.  
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4.7.6 Determination of subcellular localization 
For an investigation of the cellular localization of proteins, cell lysates can be analyzed by differential 
centrifugation to separate subcellular compartments. 
Whole Sf9 cell lysate (400µl) was centrifuged for 15 min at 800g to separate the nucleic fraction (N) 
from the cytosolic fraction (CytoI). The 800g pellet was homogenized in 400 µl 0.1 M phosphate buffer 
(pH 7.4) and centrifuged for 15 min at 8000g to pellet nuclei (N-8000g) (incubate on ice). The 800g 
supernatant (CytoI) was further processed to separate mitochondria from microsomal proteins. 
Mitochondria were pelleted after centrifugation for 15 min at 6.000g (6000g (Cyto)). The pellet was 
resolved and homogenized in 400 µl 0.1 M phosphate buffer to form mitochondrial fraction and stored 
on ice. Microsomal proteins were separated from pure cytosol by centrifugation at 100.000g (100.000g 
(CytoI)) for 1h (Beckmann Optima™TLX Ultracentrifuge; TLA 100.3, 100K RPM, S.N. 2809) and pellet 
was resolved and homogenized in 400µl phosphate buffer. The fractions were analyzed by western 
blot.  
 
Figure 4-4: Complete overview on the different centrifugation steps for subcellular centrifugation. 
 
4.7.7 Quantification of EH3  
For calculation of the kinetic constants of EH3, the enzyme was immuno quantified in insect cell 
lysates. First, recombinant EH3 obtained as inclusion bodies in E. coli was washed in Tris-buffered 
saline (Tris-HCl, 20 mM, NaCl, 100 mM, pH 8.0). Inclusion bodies were recovered by centrifugation 
and dissolved in high SDS sample buffer (sodium dodecyl sulfate, 5 %, glycerol, 8 %, 2-
mercaptoethanol, 3.3 %) to yield a final concentration in of 0.6 µg/µl. Ten microliters of 1:1 serial 
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dilutions of the dissolved EH3 protein were analyzed by SDS-PAGE and coomassie staining. The 
density of the protein bands was compared to samples with known, increasing concentrations (0.25 – 
2 µg per lane) of a bovine serum albumin. Gels were photographed with the digital camera of a gel 
documentation system (GeneFlash®, Syngene, Cambridge, UK) and band intensities were quantified 
with the public domain software package ImageJ (NIH, USA), using the routines of the Analyze/Gels 
sub menu. ImageJ is an image processing and analyzing program that was used to quantify on the 
basis of grey level after signal density calibration. Pictures (.tiff) from coomassie gels and western 
blots were imported and the respective lanes that included the band of interest were marked, and 
density was measured. The resulting plot showed the density profile. The respective area under the 
curve was analyzed and used for calibration of density signals and hence quantification of proteins. 
The obtained calibration curve for EH3 signals from western blot was fitted with non linear regression 
by using the GraphPad PRISM® software. 
 
4.8 Enzymatic activity assays 
4.8.1 CDNB assay 
The CDNB (1-chloro-2,4-dinitrobenzene) assay is used to detect the enzymatic activity of GST fusion 
proteins. The conjugation of CDNB with glutathione (GSH) by GST forms a product that can be 
measured at 340 nm. Bacterial lysates (corresponding to 5 µg total protein) disrupted by a French® 
pressure cell press were incubated at 37°C with 1mM  GSH and 100µM CDNB diluted in reaction 
buffer (0.1M potassium buffer, pH 6.5) in a total volume of 200µl in a 96 well plate. Absorbance at 
340nm was measured continuously using a SpectraMax GeminiXS plate reader (Molecular Devices) 
and SoftMax software for analysis. 
 
4.8.2 Activity assay using radio labeled substrates 
The radio labeled substrates [1-14C] styrene 7,8-oxid or [1-14C] 9,10 epoxystearic acid were used for 
analysis of epoxide hydrolase activity (Arand, Cronin et al. 2005). The activity of recombinantly 
expressed protein was assayed in the presence of 100 µM [1-14C] styrene 7,8-oxid (Arand, Cronin et 
al. 2003) or 1 µM [1-14C] 9,10 epoxystearic acid (Muller, Arand et al. 1997). 20 µl of bacterial lysates 
(16 µg/µl total protein in 0.1M phosphate buffer, pH 7.4) or 4.5 – 6x104 cells in 0.1M phosphate buffer 
(pH 7.4) were added to the buffer/substrate mix to reach a final volume of 200 µl and 100 µl 
respectively. After incubation at 37°C for 10 minut es, organic solvent was added and samples were 
vortexed and processed as follows: styrene oxide turnover was terminated by adding one volume 
(200µl) chloroform and the samples were centrifuged for 5 min at 14.000 rpm to extract the reaction 
product into the aqueous phase. 100µl of the upper phase was added to 2 ml Rotiszint® ecoplus 
(Roth, Germany) and radioactivity was measured using a liquid scintillation counter (Liquid scintillation 
analyzer TRI-CARB 2000 CA, Packard, Germany). ESA (9,10 epoxystearic acid) turnover was 
terminated by adding 2 volumes ethyl acetate. The suspension was centrifuged for 5 minutes at 
14.000 rpm and 50 µl of the organic phase were spotted on a silica-gel 60 F254 plate. The thin layer 
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chromatogram was developed in n-hexane/diethyl ether/formic acid (30:70:2) buffer and exposed to a 
Storage Phosphor Screen and scanned in the Packard CycloneTM Storage Phosphor Scanner. 
4.8.3 Activity assay using LC-MS/MS 
LC-MS/MS analysis was used to test for a specific epoxide hydrolase activity towards different lipid 
derived epoxides (with proven or assumed physiological activity) and to determine kinetic parameters. 
Enzymatic activity of EHs was assayed by determining the formation of the corresponding dihydrodiol 
products. 
 
4.8.3.1 Substrate screening I (EpOMEs, Hepoxilins, 19(20) EDPE, 17(18) EETeE) 
To test for a specific activity towards19(20) EDPE, 17(18) EETeE, 9(10) EpOME, 12(13) EpOME, 
HxA3 and HxB3, 20µl EH3 or control lysate (infected with Rv3790; corresponding to 14ng enzyme) 
was incubated with the respective substrate for 15 – 30 min at 37°C at a final concentration of 3 µM 
(EpoMEs, 19(20) EDPE, 17(18) EETeE) and 6µM (hepoxilins, Hxs) in assay buffer (10mM Tris, 1mM 
EDTA, 100mM NaCl, 6% Glycerol, pH7.4). Activity towards 19(20) EDPE and 17(18) EETeE was 
assayed by adding substrate to 20µl EH3 lysate (0.3 ng/µl) to reach a final concentration of 3 µM. For 
selective inhibition of EH3 turnover, samples were preincubated on ice with 1µM AUDA for 5 minutes 
before substrate was added. Enzymatic reaction was stopped by adding AcN (acetonitrile) to a total 
volume of 100 µl. Samples were centrifuged (10 min, 14.000 rpm) and analyzed by LC-MS/MS. 
 
4.8.3.2 Substrate screening II (2-14(15)-EG / 2-14(15) EET ethanol amide)  
To assess hydrolase activity towards 2-14(15)-EET ethanol amide (14(15)-EET-EA) and 2-(14(15)-
epoxyeicosatrienoyl) glycerol (2-14(15)-EG) the formation of the corresponding diols 2-(14(15)-
dihydroxyeicosatrienoyl) glycerol (2-DHG) or 2-(14(15)-dihydroxyeicosatrienoyl) ethanol amide (2-
DHEA) was determined. 200µl aliquots of control infected or EH3 expressing Sf9 cell lysates were 
centrifuged (45 min, 50.000rpm) and the pellet was homogenized in 60µl assay buffer (10mM Tris, 
1mM EDTA, 100mM NaCl, 6% Glycerol, pH7.4). 30 µl homogenate or hsEH (5 ng/µl) was incubated 
for 30min at 37°C with 6.8 µM 14(15)-EET-EA and 5.8 µM 2-14(15)-EG respectively. Reaction was 
quenched by addition of 1 volume ethyl acetate to reach a final volume of 60 µl. After vortexing and 
centrifugation 30 µl of the upper phase was transferred to a fresh tube and solvent was evaporated 
under a stream of nitrogen, before resolving in 60 µl methanol and subsequent analysis by LC-
MS/MS. 
 
4.8.3.3 Determination of kinetic parameters and inhibitor studies 
Substrate was added to 20µl EH3 (0.3 ng/µl), EH4 or mock expressing Sf9 cell lysates to the final 
concentration of 1-33 µM (leukotoxin) and 1-50 µM (EET regioisomers) in assay buffer (10mM Tris, 
1mM EDTA, 100mM NaCl, 6% Glycerol, pH7.4) to determine kinetic parameters. Cell lysates were 
incubated at 37° for 5 min (leukotoxin) and 10 min (EET regioisomers) respectively. For inhibitor 
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assays of EH3 (0.3 ng/µl), Sf9 lysates and purified human sEH (0.5 ng/µl) were preincubated with 
various EH inhibitors (1 µM) or AUDA (1 nM - 1 µM) for 5 min on ice, prior to addition of 8(9) EET to a 
final concentration of 5 µM (inhibitors were kindly provided by Dr. Christophe Morriseau, University of 
Davis, California). Enzymatic reaction was stopped by adding acetonitrile to a final volume of 100 µl. 
The sample was centrifuged (5 min, 14.000g) and transferred to a MS vial and submitted to LC-
MS/MS analysis. To calculate the catalytic constants the data were analyzed by kinetic modeling 
based on the equation V = E * CS/ (CS+Km) (where V is turnover in % of Vmax, E total amount of 
enzyme, CS is substrate concentration and Km refers to michaelis menten constant) assuming that V 
is in proportion to the amount of enzyme substrate complex formed and that substrate is present in 
excess. 
 
4.9 LC-MS/MS analysis 
4.9.1  I: EpOMEs, EETs, Hepoxilins, 19(20) EDPE, 17(18) EETeE 
The sample separation was performed on an Agilent eclipse XDB-C18 reverse phase column (4.6 x 
150 mm, 5 µm pore size) with a corresponding opti-gard pre-column using an Agilent 1100 liquid 
chromatography system. The mobile phase consisted of (A) 0.1% formic acid and (B) acetonitrile 
containing 0.1% formic acid at a flow rate of 400 µl/min (injection volume was 20 µl). HPLC conditions 
were identical for all substrates (EET regioisomers, leukotoxin, isoleukotoxin), except for Hepoxilin A3 
and B3. Starting conditions of 70% buffer B were maintained for 2 min, followed by a linear gradient 
from 70% to 100% B within 8 min and 6 min (HxA3, HxB3), respectively. An isocratic flow of 100% B 
was held for 4.5 min (2.5 min HxA3/HxB3) and finally the column was re-equilibrated for 2 min with 
70% B. At these conditions the compounds resolve at the following retention times as shown in the 
table below: 
 
analyte transition [amu] retention time [min] 
9,10 EpOME 295.2 → 171.1 14.1 
12,13 EpOME 295.2 → 195.1 13.5 
9,10 DiHOME 313.2 → 201.1 7.3 
12,13 DiHOME 313.2 → 183.1 6.6 
14,15 EET 319.2 → 301.1 12.8 
14,15 DHET 337.2 → 206.9 6.8 
11,12 EET 319.2 → 167.1 13.18 
11,12 DHET 337.2 → 166.8 6.86 
8,9 EET 319.2 → 301.1 14.2 
8,9 DHET 337.2 → 126.8 8.8 
HxA3 335.2 → 273.3 7.47 
TrxA3 353.3 →126.9 4.18 
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HxB3 335.3 →316.9 8.06 
TrxB3 353.3 → 195.1 4.73 
19,20 EDPE 343.3 → 299.2 12.1 
19,20 DiHDPE 361.3 → 272.9 6.17 
17, 18 EETeE 317.2 → 299.0 10.7 
17, 18 DiHETeE 335.2 → 246.9 5.46 
Table 4-3: Respective retention times and transitions of the analytes used in LC-MS/MS assay. 
 
The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole linear ion trap mass 
spectrometer (Applied Biosystems) equipped with a TurboV source and electrospray (ESI) interface. 
Analytes were recorded using multiple reaction monitoring (MRM) in negative mode (-MRM) using the 
following source specific parameters: IS -4500V, TEM 450°C, curtain gas (CUR = 30), nebulizer gas 
(GS1 = 50), heater gas (GS2 = 70) and collision gas (CAD = 10). The compound specific parameters 
for the different substrates are represented in table 4-4. 
 
analyte transition CE DP 
9,10 EpOME 295.2 → 171.1 -17 -55 
12,13 EpOME 295.2 → 195.1 -17 -55 
9,10 DiHOME 313.2 → 201.1 -23 -60 
12,13 DiHOME 313.2 → 183.1 -23 -60 
14,15 EET 319.2 → 301.1 -16 -70 
14,15 DHET 337.2 → 206.9 -26 -70 
11,12 EET 319.2 → 167.1 -18 -65 
11,12 DHET 337.2 → 166.8 -26 -70 
8,9 EET 319.2 → 301.1 -16 -70 
8,9 DHET 337.2 → 126.8 -28 -70 
HxA3 335.2 → 273.3 -20 -80 
TrxA3 353.3 →126.9 -36 -55 
HxB3 335.3 →316.9 -16 -55 
TrxB3 353.3 → 195.1 -16 -55 
19,20 EDPE 343.3 → 299.2  -16 -70 
19,20 DiHDPE 361.3 → 272.9 -24 -90 
17, 18 EETeE 317.2 → 299.0 -16 -85 
17, 18 DiHETeE 335.2 → 246.9 -24 -95 
Table 4-4: Specific parameters for different compounds analyzed in LC-MS/MS. EP (entrance 
potential) value is -10 for all analytes. DP: declustering potential, CE: collision energy. 
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All parameters were determined by direct infusion of standard solutions (100-300 ng/ml) in acetonitrile 
at a flow rate of 10 µl/min using the quantitative optimization function of the Analyst software 1.4.2. 
Samples were quantified by determining the peak AUC with the quantitation function of the Analyst 
software using the transitions as specified above. The background noise was assessed by analyzing 
blank samples and standard curves were generated using blank samples spiked with a series of 
control lipids ranging from 10-1000 ng/ml. For EpOMEs and DiHOMEs the limit of detection (LOD) was 
1ng and 20 pg, and the limit of quantification (LOQ) was 3 ng and 200 pg (corresponding to a signal-
to-noise ratio of 3 and 10). 
 
4.9.2  II: 2-14(15)-EG (2-EG) / 2-14(15) EET Ethanolamide (2-EET-EA) 
Neutral arachidonic acid derivatives were analyzed using silver cation coordination tandem mass 
spectrometry. This method uses the ability of silver cations to bind to the backbone of unsaturated 
fatty acids to form a charged complex [M + AG]+. The complexes are easily analyzed by electrospray 
ionization in the positive mode. Silver ion coordination results in the detection of two characteristic [M 
+ AG]+ complex ions due to the natural isotopic distribution of silver 107Ag (52%) and 109Ag (48%) 
(Kingsley and Marnett 2003). 
The sample separation was performed on an Agilent eclipse XDB-C18 reverse phase column (3.2 x 
100 mm, 5 µm pore size) with a corresponding opti-gard pre-column using an Agilent 1100 liquid 
chromatography system. The mobile phase consisted of (A) 70 µM AgNO3 in H2O (B) 70 µM AgNO3 
in methanol at a flow rate of 400 µl/min using an injection volume of 20 µl. Starting conditions of 50% 
buffer B were maintained for 1 min, followed by a linear gradient from 50% to 100% B within 3 min. An 
isocratic flow of 100% B was maintained for 5 min before the column was re-equilibrated for 2 min with 
50% B. At these conditions the compounds resolve at the following retention times as shown in table 
4-5. The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole linear ion trap mass 
spectrometer (Applied Biosystems) equipped with a TurboV source and electrospray (ESI) interface. 
Analytes were recorded using multiple reaction monitoring (MRM) in positive mode (+MRM) using the 
following source specific parameters: IS 4500V, TEM 450°C, curtain gas (CUR = 20), nebulizer gas 
(GS1 = 50), heater gas (GS2 = 70) and collision gas (CAD = 10). All parameters were determined by 
direct infusion of standard solutions (100-300 ng/ml) in methanol at a flow rate of 10 µl/min using the 
quantitative optimization function of the Analyst software 1.4.2. Samples were quantified by 
determining the peak AUC with the quantitation function of the Analyst software 1.4.2 using the 
transitions as specified below (table 4-6).  
 
analyte transition [amu] retention time [min] 
2-EG 501→ 106 1.9 
2-DHG 519→ 106 1.6 
2-EET-EA 470→ 452  1.6 
2-DHEA 488→ 106 1.4 
Table 4-5: Respective retention times and transitions of the analytes used in MS assay. 
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Figure 4-6: Compound specific parameters for different compounds analyzed in LC-MS/MS. 
EP (entrance potential) value is 10 for all analytes. DP: declustering potential, CE: collision 
energy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
analyte transition CE DP 
2-EG 501→ 106 77 81 
2-DHG 519→ 106 75 81 
2-EET-EA 470→ 452  31 66 
2-DHEA 488→ 106 91 91 
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5 RESULTS 
Note: In the following chapter (5.1), the label “nEH2” refers to EH4, since the former term for the novel 
epoxide hydrolase EH4 was nEH2. The proteins encoded on the respective expression plasmids are 
labeled after the vector (example: the protein produced by plasmid pGEFHisCnEH2AB is labeled 
nEH2AB). The alternative term (e.g. EH4AB) is given in brackets. 
 
5.1 Characterization of EH4 
The objective of the first part of this work was to investigate the human EPHX4 gene (also known as 
ABHD7) and its coding protein EH4 towards epoxide hydrolase activity, in order to characterize a 
putative new member of the epoxide hydrolase family. The characterization of EH4 implies two main 
approaches: i) the recombinant expression of enzymatically active protein in prokaryotic and 
eukaryotic cells, for analysis of enzymatic activity, and ii) the generation of an antibody against EH4 
for detection of the protein in recombinant lysates and tissues.  
 
5.1.1 In silico characterization of EH4 
The human EPHX4 gene (GeneID: 253152, HGNC: 23758) is located on human chromosome 
1p.22.1. Other names referring to this gene are ABHD7, EPHXRP and FLJ90341. The gene contains 
7 exons and 6 introns and the resulting mRNA is 1635 bp long. The predicted protein consists of 362 
aa with a molecular weight of 42.3 kDa (pI 8.0) 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html?human) {Thierry-Mieg, 2006 #7}. 335 
bp of the gene are antisense to spliced gene prada (GenBank: BM723110.1). The EH4 protein 
(UniProtKB/Swiss-Prot Q8IUS5) is encoded with two amino acid variations Y321F and F285I, of which 
the first one is likely a natural variant (SNP, single nucleotide polymorphism) {Gerhard, 2004 #9} and 
the latter one is based on a sequence conflict {Ota, 2004 #8}. The protein investigated in this work 
contains a phenylalanine residue at position 321 and 285 (see appendix 8.3.1). Residues 17 – 37 
indicate a potential signal-anchor for type II membrane proteins, based on results from protein 
sequence analysis software tools (http://www.uniprot.org/uniprot/Q8IUS5). Other in silico analyses 
using the database MitoProt II (v1.101; {Claros, 1996 #16}) and the NetCGlyc 1.0 Server 
(http://www.cbs.dtu.dk/services/NetNGlyc/) point towards a mitochondrial targeting sequence 
(cleavage site at position 58), and predict C mannosylation at position 106. The EPHX4 gene is 
present in chimpanzee (99%), dog (94%), mouse (98%), rat (89%), chicken (82%), and zebra fish 
(67%) and shares high sequence identity with the human protein (% identity given in brackets). The 
closest c. elegans gene is ceeh-1 (42%; UniProt: Q21147). The overall expression of EPHX4 is low. A 
comparison of the available expression data indicates, that the gene is mostly expressed in the central 
and peripheral nervous system, mainly brain, eye and dorsal root. Moreover, expression is detected in 
intestine, blood and adipose tissue. 
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5.1.2 EH4 expression constructs 
To investigate the putative enzymatic activity of the protein, enzymatically active EH4 was 
recombinantly expressed by different eukaryotic and prokaryotic expression systems. To further obtain 
a sensitive and specific detection tool for identification of the protein in cell lysates and/or tissues, 
different EH4 fragments were expressed in E. coli for production of an antibody. All vector, primer and 
protein sequences, and also PCR conditions used in the following experiments, are listed in the 
appendix (see 8.1). 
 
5.1.2.1 E. coli expression constructs 
In this study, following constructs were produced: His-tagged constructs were generated for 
production of an EH4 specific antibody, and to investigate if specific peptides of the protein are critical 
for expression. The plasmid pGEFGSTNnEH2 was constructed for investigation of the enzymatic 
activity of EH4 in E. coli, whereas pGEFGSTNnEH2AB was produced to investigate the influence of 
GST fusion on expression and solubility of the recombinant protein. All His-tagged EH4 fragments 
(see table 5-1) were generated through cloning into the pGEF-HisC Vector. Since production and 
expression of functional eukaryotic membrane proteins is difficult in bacterial expression systems, the 
membrane anchor (aa 1 – 59) was deleted in the nEH2AB (EH4AB) protein. Furthermore, the two 
putative active sites D307 and H336 were removed to avoid any toxicity of the protein to the bacterial 
host, which would lead to negative selection. The primers used for amplification of the respective 
cDNA contained restriction sites for BglII and BspHI, which were used for insertion of the cDNA into 
the MCS of pGEF-HisC by NcoI and BglII II restriction sites. Since the expression of His-tagged 
nEH2AB (EH4AB) protein in E. coli failed, two parts of the protein sequence were expressed 
separately to identify if any of the protein parts includes critical peptides that prevent expression. The 
different protein parts contain either the membrane anchor (1/3) or C-terminal parts of the α/β 
hydrolase fold (3/3). The PCR product of both inserts for construction of nEH2_1/3 (aa 1-118; 
EH4_1/3) and nEH2_3/3 (aa 267-362; EH4_3/3) contained NcoI I and BglII restriction sites, which 
were introduced with the respective primers and allowed cloning into the NcoI I/BglII digested pGEF-
HisC vector. The mammalian expression construct pIRESneonEH2 was used as template for the 
amplification of the respective cDNAs (see 5.1.2.2). 
 
expression plasmid template vector primer restriction sites 
pGEFHisCnEH2AB IRAK pGEF-HisC # 3 # 4 
BspHI 
BglII 
pGEFHisCnEH2_1/3 pIRESneonEH2 pGEF-HisC # 5 # 6 
NcoI 
BglII II 
pGEFHisCnEH2_3/3 pIRESneonEH2 pGEF-HisC 
# 7 
# 8 
NcoI 
BglII II 
Table 5-1: Overview of C-terminal His-tagged E. coli expression constructs (see appendix for primer 
sequences). 
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Parallel to the generation of the His-tagged EH4 fragments, two different N-terminal tagged expression 
constructs were produced (table 5-2). Both constructs are deficient in the membrane anchor (aa 1-59) 
but differ in the presence of the putative active sites D307 and H336. The GST-nEH2 (GST-EH4) 
protein covers aa 60 - 354 of the EH4 protein and was constructed to investigate enzymatic activity of 
EH4. The respective construct (incl. D307 and H336; GSTnEH2/GSTEH4) was constructed by 
EcoRI/NdeI restriction of the pGEFnEH2HisC plasmid. This plasmid contains the complete 3` 
sequence of EH4. The resulting EcoRI/NdeI fragment was subcloned into pGEFGSTNnEH2AB 
(described below) by using the same restriction sites. GST-nEH2AB (GST-EH4AB) lacks 60 C-
terminal amino acids and corresponds to the protein encoded by pGEFHisCnEH2AB. The construct 
was used to investigate the influence of N-terminal fusion with GST on the expression of truncated 
EH4. For production of the C-terminal truncated expression construct (pGEFGSTNnEH2AB), an 
intermediate construct – ToponEH2AB – was digested with BspHI andBglII and subcloned into 
NcoI/BamHI digested pGEF-GSTN vector, employing the compatibility of NcoI/BspHI and BglII/BamHI 
restriction sites. 
Table 5-2: Overview of N-terminal GST-tagged E. coli expression constructs and cloning details. 
 
5.1.2.2 Mammalian cells expression constructs 
Eukaryotic expression constructs provide posttranslational modification, which may be critical for 
expression of enzymatically active proteins. In terms of functional characterization of EH4, an 
expression construct for recombinant expression in mammalian cells was prepared (table 5-3). The 
cDNA coding for the complete sequence of EH4 was amplified from the IRAK plasmid and cloned into 
pIRESneo using EcoRV and BamHI restriction sites. 
Table 5-3: Generation of the pIRESneo expression construct for expression in mammalian cells (see 
appendix for primer sequences and PCR conditions). 
 
5.1.2.3 Sf-9 expression constructs 
Besides mammalian cells, insect cells are another eukaryotic expression system used for recombinant 
expression of heterologous proteins. Previous work in our lab showed that EH3 can be enzymatically 
active expressed in Sf9 cells. Therefore EH4 expression constructs for Sf9 cells were generated 
(containing the complete cDNA) to investigate enzymatic activity of EH4. As demonstrated by 
Pendergast and Luckow {Pendergast, 1989 #6; Luckow, 1988 #7}, GC rich 5` non - coding sequences 
can affect the expression level and mRNA stability of heterologous proteins that are recombinantly 
expressed in Sf9 cells. For this reason, a modified shuttle vector (pFastBacmod) was generated, 
expression plasmid donor plasmid A receiving plasmid B restriction A restriction B 
pGEFGSTNnEH2AB TOPOnEH2AB pGEFGSTN BspHI/Bgl II NcoI/BamHI 
pGEFGSTNnEH2 pGEFnEH2HisC pGEFGSTNnEH2AB EcoRI/NdeI EcoRI/NdeI 
expression plasmid template vector primer restriction sites 
pIRESneo-nEH2 IRAK pIRESneo # 1 # 2 EcoRV/BamHI 
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where the ATG start codon of the novel introduced NdeI restriction site corresponds to the native 
Polyhedrin wild-type start codon. Hence the original 5`GC rich sequence was eliminated. The 
pFastBacmod was constructed as follows: primer #13 bound upstream of the PolH and formed a 
BspEI restriction site, whereas primer #14 bound within the PolH and was equipped with an MCS that 
contained an NdeI recognition sequence. The resulting PCR amplificate was then cloned into 
pFastBacHis vector by using BspEI and PstI restriction endonucleases. 
To build the expression constructs that encode for His-tagged EH4, the respective PCR products 
(primer and PCR conditions see 8.1) were cloned into either the original (pFastBacHis) or modified 
(pFastBacmod) vector. Cloning into the original vector by BamHI/ PstI restriction resulted in the 
plasmid labeled Y, whereas cloning into the modified vector by NdeI/PstI restriction resulted in Bmod. 
In order to then clone the expression construct that produced non-tagged EH4 (Amod), the cDNA was 
inserted by NdeI/BamHI restriction. This resulted in a frameshift that included a stop codon before the 
His (6x) sequence. 
5.1.3 Expression of EH4 for antibody production 
For the generation and production of an antibody, the respective antigen and epitope needs to be 
present in high amount and purified. To produce the required fragments, an attempt to recombinantly 
overexpress EH4 in E. coli and purify the protein using the corresponding His-Tag was made. 
Expression of EH4 was performed using the constructs described in chapter 5.1.2.1. The expression 
of nEH2-3/3 (EH4-3/3) yielded detectable amounts of recombinant protein in E. coli lysate, and was 
used for immunization.  
 
5.1.3.1 Expression of His-tagged EH4 
Previous work in our lab showed that the expression of the full length EH4 is not possible. Therefore, 
two truncated EH4 proteins were expressed in bacteria to generate an antibody against EH4. In 
addition to that, the proteins were expressed to investigate if any of the two parts is critical and 
prevents expression. The C-terminal His-tagged EH4 protein that contains aa 267-362 was 
successfully overexpressed in E. coli, as demonstrated by coomassie staining (figure 5-1). Neither 
coomassie gel analysis nor western blot allowed detection of anchorless EH4 (pGEFHisCnEH2AB) 
and truncated EH4 protein containing aa 1-118 (nEH2-1/3; EH4-1/3). The fact, that EH4-3/3 is 
expression plasmid template vector primer restriction sites 
pFastBacmod pFastBacHis - 
# 13 
# 14 
 
(BspEI)/MCS 
Y (nEH2His) 
 
IRAK pFastBacHis # 9 # 10 BamHI/Pst I 
Amod (nEH2) IRAK pFastBacmod # 11 # 2 NdeI I/BamHI 
Bmod (nEH2His) IRAK pFastBacmod # 11 # 10 NdeI/Pst I 
Table 5-4: Overview of Sf-9 expression constructs (see appendix for primer sequences). 
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overexpressed in E. coli and expression of EH4 1/3 failed, suggests that at least the first N-terminal 
amino acids are critical for expression in E. coli. 
 
 
Expression of EH4-3/3 (nEH2-3/3) in BL21AI indicated formation of inclusion bodies. For affinity 
chromatography, the proteins needed to be resolved. To analyze whether the protein is present in 
protein aggregates or insoluble inclusion bodies, the pellet obtained after centrifugation of bacterial 
lysate was washed with Triton containing buffer (100mM Tris, 200mM NaCl, 1mM EDTA, 0.5% Triton, 
0.02% NaN3, pH 7.8). Figure 5-2 shows that the majority of the protein is still present in the pellet after 
washing with Triton wash buffer. This indicates that the most of EH4-3/3 was present in insoluble 
inclusion bodies and not in protein aggregates (figure 5-2). 
 
5.1.3.2 Purification of His-tagged EH4 
In order to purify EH4-3/3 by affinity chromatography, the protein needs to be resolved from the 
inclusion bodies. The pellet was resolved in ib-buffer (6M Urea, 100mM Tris, NaN3, pH 8.5) at room 
temperature ON, prior to affinity chromatography. Although denaturing conditions generally do not 
affect binding of histidine residues to chelating sepharose, there was no specific binding of EH4-3/3 
Figure 5-2: Resolving protein aggregates. 
EH4-3/3 containing pellets were washed with 
triton buffer to resolve any protein aggregates 
present in the pellet. The majority of protein is 
still present in the pellet after treatment with 
TritonX wash buffer, indicating that the 
protein is present in insoluble aggregates 
(inclusion bodies). 
Figure 5-1: Expression of EH4-3/3 (nEH2-3/3; 
12.5 kDa) in BL21AI. Expression was induced 
with 20µM at OD600~0.4 and continued ON at 
18°C. Bacterial cells were disrupted by French® 
press and analyzed by SDS-PAGE. Lane 1: 
Marker, Lane 2 and 3: lysates of EH4-1/3 
expressing E.coli. 
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(nEH2-3/3) to the matrix, as demonstrated by coomassie gel analysis of the different elution fractions 
(figure 5-3). Analysis of the remaining fractions revealed that all protein was present in the flow-
through. 
Several other approaches to purify the protein by size exclusion or anion exchange failed. Yet, the 
protein present in the above fraction was pure enough to be used for immunization. 
 
5.1.3.3 Production of specific antibodies using EH4-3/3 
The protein fractions were concentrated by VIVA spin technique, submitted to SDS-Page (0.4 mg 
total, 0.1 mg per band) and the protein was excised from the PAA gel and sent for immunization. 
Immunization followed a 3-month protocol with 4 injections (day 0, 14, 28 and 56) of which each 
contained 0.1 mg protein. The antibody was raised in rabbit. Pre-immune serum (2ml, day 0), serum 
from small bleed (2ml, day 38), large test bleed (20ml, day 66) and final bleed (day 87, 50ml) were 
obtained and tested for immuno reactivity against EH4 expressed in Sf9 cells and GST-tagged EH4 
expressed in E. coli. Figure 5-4 A shows a coomassie staining of GST and GST-EH4 expressed in 
E. coli. Samples of the same lysate (GST and GST-EH4) were blotted onto PVDF membrane and 
incubated with EH4 - antiserum (final bleed) at a dilution of 1:1000 (figure 5-4 B). There was no 
specific detection of EH4 compared to the negative control (GST-lysate only) observed. Altering the 
dilution of the antiserum (1:500, 1:2000 and 1:10.000) as well as the antigen (EH4-3/3) showed 
unspecific binding of the antibody in the EH4 sample and the negative control.  
Figure 5-3: Purification of His tagged EH4-3/3 (nEH2-3/3) by 
affinity chromatography. Resolved EH4-3/3 inclusion bodies 
were submitted to affinity chromatography as described in 
materials and methods. There is no binding of EH4-3/3 to the 
His-Trap column and the protein is present in the flow-through 
(unbound proteins). 
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Since the protein for immunization was expressed in E. coli and excised from a PAA gel, the 
unspecific binding and the background might arise from crossover reaction with other E. coli proteins 
present in the lysate. Therefore, the immune serum was also tested against EH4 protein that was 
recombinantly expressed in Sf9 cells. His-tagged EH4 was analyzed by western blot (using α-His 
antibody) to confirm the presence of EH4 in the cell lysate (figure 5-5). The same samples were 
blotted again and incubated with the EH4 immune serum (1:1000) to test for specific immuno reactivity 
with EH4 (figure 5-6). A band is visible at the expected molecular weight, however the immune 
reactivity was far too unspecific and the negative control showed a band at the same height, which 
disallows differentiation between EH4 specific and Sf9 unspecific signals. 
Figure 5-5: Western blot analysis of EH4 -His 
expressed in Sf9 cells using α-His antibody 
(1:1000). There is specific detection of EH4-
His protein visible in the pellet. There is no 
protein present in the SN. (-) control: control 
infected Sf9 cells. (+) control: His tagged 
mycoVI (39kDa). Bmod and Y refer to 
different expression constructs that encode 
for EH4-His, but differ in the upstream DNA 
sequence (see materials and methods). 
Figure 5-4: Test of EH4 
antiserum (rabbit, final bleed) 
obtained after immunization 
with EH4-3/3 (nEH2-3/3). Over 
expression of GST and GST-
EH4 is visible after coomassie 
staining (A). There is no specific 
immuno reaction with GST-EH4 
visible in western blot analysis 
with the EH4 immune serum 
(B). Dilution of EH4 antiserum: 
1:1000. GST-lysate served as 
negative control.  
A B 
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Alternatively, two synthetic peptides (DPSLGTHCYVRIKDS and EGSHWLQQDQPDIVN) 
corresponding to the EH4 from mouse, were used for generation of an antibody. The sequence 
similarity is sufficient to expect a cross reaction with EH4 from human.  
Figure 5-7 shows the immunoreactions of one generated peptide antibody (DPSLGTHCYVRIKDS) 
against lysate of EH4 expressing Sf9 cells. There was no specific detection of EH4 visible. The above 
results showed that the EH4 immune sera obtained after immunization with truncated protein as well 
as synthetic peptides cannot be used for specific detection of EH4 protein in E. coli and Sf9 cell lysate.  
 
5.1.3.4 Peptide analysis by LC-MS/MS 
Since the different immune sera failed to specifically detect EH4 protein, an alternative method based 
on peptide analysis by LC-MS/MS was established for detection of (untagged) EH4 in Sf9 cell lysates. 
For this purpose, proteins were isolated by methanol extraction from pelleted EH4 expressing insect 
cells and analyzed by LC-MS/MS as described in materials and methods. The obtained peptide 
spectrum was blasted against a human protein database, and the resulting matches were analyzed. 
The best match was in fact human EH4. This was a significant result as indicated by the high 
Figure 5-7: Western blot 
analysis of EH4 expressed in 
Sf9 cells, using immune serum 
generated against a synthetic 
peptide. There is no specific 
detection of the peptide 
antibody with EH4 visible. 
Bmod and Y refer to different 
expression constructs that 
encode for EH4-His, but differ 
in the upstream DNA sequence 
(see materials and methods). 
Figure 5-6: Western blot analysis of EH4-His 
expressed in Sf9 cells using EH4 antiserum 
(final bleed). There is no specific immuno 
reactivity of the antiserum with EH4 visible. 
Bmod and Y refer to different expression 
constructs that encode for EH4-His, but differ in 
the upstream DNA sequence (see materials 
and methods). 
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probability based mowse (molecular weight search) score of 310 (figure 5-8). The score indicates the 
probability that the observed match is a random event. The green region indicates the significance 
level and scores within this region are of no significance (in this case a probability score of 42). Hence 
the score of 310 confirmed the presence of EH4 in the investigated sample. This method could be 
used as an alternative to detect specific proteins independent from immunoblotting. 
 
 
Figure 5-8: Probability based MOWSE (molecular weight search) score of the Mascot search results. 
The best match observed was human EH4 with a probability score of 310. This result is significant. 
The green shaded region marks the significance level. Scores within the green region are not 
significant.  
 
Figure 5-9 shows the amino acid sequence of EH4 and the matching peptides (highlighted in bold 
red). Altogether, 9 different peptides matched with the human protein database and resulted in the 
identification of EH4 (figure 5-9). Both EH4 and His-tagged EH4 were detected in methanol extracts 
from pelleted insect cells but not from the supernatant of Sf9 cultures. This indicates that EH4 is most 
likely not secreted. 
 
 
 
 
Figure 5-9: Primary sequence of EH4.The peptides that matched in a BLAST search against 
human proteins are shown in bold red. 
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5.1.4 Expression of EH4 for functional characterization in E. coli  
In order to investigate and characterize enzymatic activity of EH4, prokaryotic and eukaryotic cell 
lysates containing theoretically active protein (including all putative catalytic residues) were submitted 
to activity assays. Expression and activity measurements of EH4 from E. coli, Cos-7, V79 and Sf9 
cells are described below. 
 
5.1.4.1 Expression of GST-tagged EH4 (E. coli) 
Anchorless EH4 was expressed with an N-terminal GST-tag to investigate enzymatic activity of EH4. 
A truncated EH4 protein (GST-EH4AB), lacking the putative catalytically active residues D307 and 
H336, was parallel expressed. This was done in order to investigate the influence of GST fusion on 
expression and solubility of truncated EH4. As figure 5-10 depicts, N-terminal fusion with GST led to 
visible overexpression of both EH4 proteins, the truncated protein deficient in D307 and H336 
(GSTnEH2AB/GST-EH4AB) and the protein only lacking the membrane anchor (GSTnEH2/GST-
EH4). This result showed that N- terminal fusion influences and improves the expression of EH4 in 
bacteria, because previous attempts to express the C-terminal tagged (His) truncated EH4 protein 
(nEH2ABHis, EH4ABHisC) for antibody generation in E. coli was not possible. The majority of both 
recombinant proteins was present in the supernatant, most likely as a result of GST fusion. Fusion 
with GST is known to increase probability of directing the recombinant protein into the cytosol. 
 
5.1.4.2 CDNB assay 
For affinity purification of GST-tagged proteins, it is necessary that the GST fusion protein is folded 
correctly. Since the enzymatic activity of GST correlates with the correct folding of the protein, a 
CDNB assay was performed to analyze the activity of GST. The assay measures the conjugation of 
the synthetic GST substrate CDNB (1-chloro-2,4-dinitrobenzene) with reduced glutathione, and was 
performed as described under materials and methods. Native glutathione transferase (GST) shows 
Figure 5-10: Expression of N-terminal 
GST-tagged EH4. Expression of GST, 
GST-nEH2AB (GST-EH4AB) and GST-
nEH2 (GST-EH4) in Bl21AI was induced 
with 20µM arabinose at OD600~0.4 and 
continued over night at 18°C. Bacterial 
pellet was resuspended in 0.1M NaPO4, 
pH 7.4 and disrupted by French® 
pressure cell press. Molecular weights 
are 28kDa (GST), 56kDa (GST-nEH2AB) 
and 62kDa (GST-nEH2). (P): pellet (10 
min, 13.000 rpm) and (S): Supernatant. 
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the highest activity in CDNB conjugation (table 5-5). However, the EH4 fusion proteins showed a 
significant GST activity as compared to the negative control, which indicated the presence of properly 
folded fusion protein. Figure 5-11 shows the corresponding graphs.  
 
 
 
 
GST GST-EH4 GST-EH4AB 
change in absorption 0.069 0.019 0.030 
specific activity [nmol/min*mg] 95.5 26.7 41.7 
Table 5-5: Conjugation of CDNB with glutathione by GST, GST-EH4 and 
GST-EH4AB. The specific activity is calculated as the increase in 
absorption per minute and mg total protein. Change in absorption at 340nm 
corresponds to 0.0096 /µM (CDNB) * cm 
 
 
 
 
 
 
 
B 
A 
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5.1.4.3 Purification of GST-tagged EH4 
Since the results of the CDNB assay indicated a correct folding of the GST fusion protein, the GST 
tagged proteins were submitted to affinity chromatography. To purify the GST tagged EH4, the 
supernatant of bacterial lysate was incubated with GSH sepharose, and affinity chromatography was 
performed as described in materials and methods. Figure 5-12 shows the SDS-Page analysis of the 
different fractions obtained. Although not all GST proteins bind to GSH sepharose, a considerable 
amount was selectively eluted from the matrix after incubation with elution buffer. 
Figure 5-11: CDNB assay with different bacterial GST constructs (A: GST, 
B: GST-EH4, C: GST-EH4AB). CDNB assay was performed with French® 
press lysates of BL21AI. GSH 1mM, CDNB 50µM, total protein was 5µg in 
all three samples. Samples were measured in triplicate every 15 sec. neg 
control: GSH and CDNB only. 
Figure 5-12: Batch purification of GST-nEH2 (GST-EH4; 62kDa) and GST-nEH2AB (GST-
EH4AB; 56kDa). Proteins were recombinantly expressed in E. coli BL21AI (18°C, ON), 
disrupted by using French® Pressure Cell Press and purified as described in materials and 
methods. (20µg protein per lane) 
C 
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In addition to the GST fusion proteins, the coomassie gel (figure 5-12) shows an additional band at 
70kDa, which is copurified and present in the elution fraction. The protein most likely corresponds to 
the bacterial Hsp70 DnaK (Pharmacia 1997). This bacterial molecular chaperone binds to the peptide 
sequence on the matrix that fuses with the GST protein and may be eliminated by washing the bound 
fusion protein with either Triton or MgATP (Pharmacia 1997; Rial and Ceccarelli 2002).  
In order to increase the amount of soluble GST-EH4 and hence the yield of purified protein, the pellet 
(4000rpm, 45 min) of the cell lysate was washed with TritonX (1%) to resolve any protein aggregates 
present in the pellet. Approximately 80% of the pelleted GST tagged EH4 proteins was resolubilised 
and present in the resulting supernatant. The Triton soluble fraction was incubated with GSH 
sepharose and purified as described in materials and methods. 
Figure 5-13 shows the SDS-Page analysis of the resulting protein fractions. As in the previous 
experiment, not all GST tagged proteins were bound to the sepharose material. Yet, there was a 
visible concentration and purification of GST-EH4 as well as GST-EH4AB visible. Some amount of 
protein was still bound to the sepharose matrix (not eluted), which is most probably a result of the 
short incubation with GSH (10 minutes). There was no copurification of bacterial chaperones visible, 
since washing with TritonX led to dissociation of these complexes and hereby prevented interaction 
with the chromatography matrix. 
A CDNB assay was performed in order to test for activity and proper folding of the eluted proteins. The 
purified GST fusion proteins showed a GST activity comparable to the crude lysate.  
 
5.1.4.4 Enzymatic activity of GST- EH4  
GST-EH4 containing all putative catalytically active residues was successfully expressed in bacteria. 
Therefore, the purified fusion protein was tested for activity towards the radioactively [1-14C] labeled 
Figure 5-13: Batch purification of TritonX soluble proteins. Proteins were recombinantly 
expressed in BL21AI (18°C, ON). The pellet obtained  after French Press disruption was 
washed in Triton buffer. Resolubilised protein was submitted to affinity chromatography. 
MW: GST-nEH2 (GST-EH4): 62kDa) and GST-nEH2AB (GST-EH4AB): 56kDa 
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substrates 9, 10-epoxystearic acid (ESA) and styrene 7, 8-oxide (STO) as described in materials and 
methods. 
As table 5-6 shows, there was notable activity of the bacterial lysates (GST, GST-EH4) compared to 
the negative control (buffer). On average, the radioactivity measured in the aqueous phase of GST 
lysate was 3 times higher than in the samples that contain the GST fusion protein. This approximately 
reflects the ratios measured in the CDNB assay, indicating that the radioactive compound present in 
the aqueous phase is most likely a GSH conjugate of styrene 7, 8-oxide.  
 
sample mean (dpm) [1-14C] STO [nmol] 
Buffer (phosphate buffer 0.1M, 7.4) 1371 - 
Lysate GST 30553 0,88 
Lysate GSTEH4 10473 0,28 
Lysate GST (BSA (1mg/ml)) 33038 0,96 
Lysate GSTEH4 (BSA (1mg/ml) 11986 0,32 
Lysate GST (Glycerol 2-5%) 32228 0,94 
Lysate GSTEH4 (Glycerol 2-5%) 13124 0,36 
Table 5-6: Enzymatic activity of GST against [1-14C] labeled styrene 7, 8-oxide. GST expressed in 
BL21AI has higher activity towards styrene-oxide as compared to the fusion protein. [1-14C] STO 
corresponds to 15 mCi/mmol. 
 
It has been shown that glutathione transferases conjugate GSH to styrene oxide (Hayakawa, 
Lemahieu et al. 1974; Hiratsuka, Yokoi et al. 1989), which leads to formation of the more hydrophilic 
GSH conjugate and is therefore extracted into the aqueous phase. It remains unclear if any 
contribution to styrene turnover was due to EH4, because the distinction between conjugate and diol is 
not possible with this assay. There was no radioactively labeled diol product detectable by TLC, when 
using [1-14C] labeled 9, 10-epoxystearic acid (ESA) as substrate. 
 
5.1.5 Expression of EH4 for functional characterization in mammalian 
cells 
Since investigation of EH4 enzymatic activity with GST tagged protein from E. coli turned out to be 
inapplicable, an eukaryotic expression system using Cos-7 and V79 cells was established as 
alternative method. Activity measurements were performed with ESA and other fatty acid derived 
epoxides.  
 
5.1.5.1 Stable expression of EH4 
EH4 mRNA was present in stably transfected Cos-7 cells. This was confirmed by RT - PCR and 
subsequent sequencing (figure 5-14). Since Cos-7 cells turned out to have endogenous EH activity 
towards the initial screening substrate 9 (10) epoxystearic acid (see 5.1.5.2), an additional cell line 
(V79) was transfected with EH4 cDNA (figure 5-15). V79 cells are deficient of at least endogenous 
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mEH, as shown by western blot analysis and activity measurements of mock transfected control cells 
towards STO turnover (Herrero, Arand et al. 1997). These cells also show very low endogenous sEH 
activity (Glatt, Gemperlein et al. 1987). 
 
 
5.1.5.2 EH4 activity analysis in transfected mammalian cell lines 
Radiolabeled substrates were used to test for activity of EH4 towards styrene 7, 8- oxide (STO), a 
substrate known to be turned over by most of the investigated EHs. Furthermore, turnover of 9(10) 
epoxystearic acid (ESA), another EH substrate that structurally refers to fatty acid derived signaling 
molecules, was investigated as described in material and methods.  
Figure 5-14: Expression of EH4 in Cos-7 
cells (clone 3). mRNA was isolated from 
stable transfected Cos-7 cells and RT 
PCR was performed with EH4 (nEH2) 
specific primer. The sequence of the 
amplificate (390bp) was confirmed by 
sequencing. GAPDH (523bp) was used 
as positive control. 
 
Figure 5-15: Expression of EH4 (nEH2) in 
different V79 stable transfected cell clones. 
mRNA was isolated from stable transfected 
V79 cells and RT PCR was performed with EH4 
(nEH2) specific primer. The sequence of the 
amplificate was confirmed by sequencing. (-): 
negative control. 
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The results of the radioactivity assay with Cos-7 cells indicated an endogenous activity towards 9(10) 
epoxystearic acid (figure 5-16). In this assay, the hydrolysis product can be identified by its different 
migration distance. The corresponding diol is more polar and thus shows a shorter migration distance 
than the epoxide. As indicated in figure 5-16, the turnover of ESA by EH4 (nEH2) transfected cells 
was about the level of Cos-7 Wt cells.  
To investigate if there was a low EH4 activity that cannot be detected by this assay, further 
experiments using LC-MS/MS analysis were performed (see appendix 8.6.1). The LC-MS/MS assay is 
a more sensitive method with higher resolution. The assay was performed in order to verify or exclude 
EH4 activity in EH4 infected cells compared to control cells. The data confirmed the results obtained 
from TLC and could not demonstrate a significant activity of EH4. Turnover of EETs as well as 
EpoMEs and cis/trans ESA (data not shown) did not exceed the level of endogenous activity observed 
in control cells. Endogenous sEH activity of Cos-7 cells has been reported by other groups measuring 
t-SO turnover (Sandberg, Hassett et al. 2000) and has also been detected by western blot analysis 
(Fang, Hu et al. 2006). For that reason, Cos-7 cells are not applicable for enzymatic activity assays 
that should investigate hydrolase activity of EH4 towards epoxy lipids, and therefore were excluded 
from the experiments.  
As alternative mammalian cell system, V79 cells were stably transfected with EH4 (figure 5-15) and 
activity measurements using LC-MS/MS were performed. Experiments with V79 Wt cells using LC-
MS/MS showed that V79 Wt cells did not have endogenous activity towards the tested epoxy lipids. 
Activity measurements did not prove hydrolysis of Hepoxilins, EETs, EpOMEs and cis/trans ESA by 
EH4 (see appendix 8.6.2). 
 
 
 
 
Figure 5-16: Endogenous turnover of 9(10) 
epoxystearic acid by Cos-7 cells. 5.4x104 
(Cos-7 Wt), 6x104 (Cos-7 nEH2 3) and 4.5x104 
(V79EH3, positive control) cells were incubated 
with [1-14C] ESA for 10 minutes at 37°C and 
analyzed by TLC. 
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5.1.5.3 Expression of EH4 for functional characterization in Sf9 cells 
Recombinant expression of the highly related EH3 in Sf9 cells resulted in the expression of enzymatic 
active protein. Therefore, a baculovirus expression system for expression of EH4 in insect cells was 
established. 
Expression of His-tagged EH4 protein was detected after infection with a multiplicity of infection (MOI) 
of 5 (figure 5-17). The MOI indicates the ratio of infectious virus particles to targeted cells, in this case 
5 virus particles per cell. In comparison, an infection with MOI 1 did not yield any detectable amounts 
of EH4 protein as indicated by WB analysis (figure 5-17). 
 
First signs of expression were detectable on day 3 post infection (dpi), and the highest expression was 
reached on day 5 and 6 (figure 5-18 A). The coomassie analysis of Sf9 proteins of Wt cells compared 
to infected cells showed an altered expression pattern (see 5.1.5.4). Yet, a clearly visible 
overexpression of the recombinant protein (figure 5-18 B) was not possible after infection with the 
modified bacmid (Bmod). Likewise, there was no sign of overexpression after infection with the 
unmodified bacmid (Y) visible. The bacmid Y encodes for the same His-tagged EH4 protein, but 
displays upstream GC rich non-coding sequences, which have been reported to influence and reduce 
Figure 5-17: Expression of EH4-His (Bmod) 
with infection of MOI1 and MOI5 at days 5-8 
post infection. 5x106 cells were pelleted daily 
and resolved in 150 µl PBS. 1x105 cells 
were mixed with laemmli and analyzed by 
Western Blot using α-His antibody. negative 
control (-) Sf9 Wt, positive control (+) PknG 
(32kDa). 
A 
B 
Figure 5-18: Expression of EH4-His (nEH2-His; Bmod) 1-7 days after infection with MOI 5. 1x106 
cells were pelleted daily and analyzed by western Blot (A). There is no overexpression detectable in 
the corresponding coomassie gel (B). neg: Sf9 Wt; +: His tagged mycoVI (39kDa), 1-7: days after 
infection. 
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heterologous expression. However, the results indicated that removing of GC rich non-coding regions 
upstream of the gene did not improve expression of EH4. 
 
5.1.5.4 Analysis of Sf9 expression pattern 
Coomassie analysis of recombinant expressed proteins in Sf9 cells led to altered expression pattern 
and to the occurrence of an additional band in recombinant EH3 and EH4 lysates, as compared to Sf9 
Wt cells (5-19). To test whether this band corresponds to EH3 and EH4, and therefore would allow the 
quantification of the recombinant expressed protein, the appropriate band was excised and analyzed 
by LC-MS/MS as described in materials and methods . 
 
The bands # 1, 2, 4, 5 and 7 are not present in Wt cells. To clarify if these bands correspond to the 
respective recombinant expressed protein, the bands were excised and analyzed by LC-MS/MS. Band 
# 3 was tested for presence of mEH since it is the dominant band at approx. 50kDa, which 
corresponds to the molecular weight of mEH (53kDa; #4 was used as negative control). The two 
protein bands # 6 and 8 were also analyzed for presence of EH3 and EH4, in case both proteins 
would have lower MW due to degradation or posttranslational modification. Peptide analysis of the 
different gel pieces resulted in significant positive results in samples # 3 (mEH; probability score 55, 
significance level 39) and 8 (EH4; probability score 274, significance level 41; see figure 5-20 (A) and 
(B)), whereas sample 1 and 6 indicated presence of EH4 and EH3, but not significantly (EH4: 
probability score 22, significance level 41 and EH3: probability score 25, significance level 43).  
 
 
 
Figure 5-19: Coomassie analysis of different proteins recombinantly expressed in Sf9 cells. 
Expression of native and His-tagged EH4 protein resulted in an additional band as 
compared to the negative control (A). Expression and coomassie analysis of expression 
pattern from novel epoxide hydrolases compared to sEH and mEH (B). Protein bands 
encircled in red were excised from the gel and analyzed by LC-MS/MS. 
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Samples 2, 4, 5 and 7 resulted in the match of different proteins as expected at least for sample 4. 
Most probably, the additional band (37kDa) observed in coomassie gel did not correspond to the 
recombinant expressed protein, but rather was an effect of infection and expression of membrane 
bound proteins. Figure 5-21 shows the coomassie analysis of Sf9 cells transfected with a putative 
bacterial Oxidoredutktase (Rv3790) compared to Sf9 Wt cells. The Rv3790 infected cells also show an 
additional band at ~ 37kDa.  
Figure 5-20: Probability Score for peptide analysis of mEH (#3, (A)) and EH4 
(#8, (B)). Both scores are significant since they are above significance level 
(green shade). 
A 
B 
Figure 5-21: Coomassie gel of Sf9 Wt cells 
and Sf9 cells infected with EH4 and Rv3790 
(control cells). The additional band at 37kDa 
observed in EH4 expressing cells is also 
present in control infected cells, but not in Sf9 
Wt cells.  
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These results demonstrate that EH3, as well as EH4, were only expressed to a low amount and that 
the additional band does not correspond to the recombinant protein. Furthermore, it was possible to 
identify peptides from proteins separated by SDS-Page and directly digested in the gel by LC-MS/MS. 
This shows that the method could be applied for detailed analysis of specific bands. 
 
5.1.5.5 EH4 activity assay in Sf9 cell lysates 
Activity measurements with Sf9 cell lysates were performed using LC-MS/MS. There was no 
significant and reproducible turnover of EETs (5(6) EET, 8(9) EET, 11(12) EET, 14(15) EET), EpoMEs 
(leukotoxin 9(10) EpoME, isoleukotoxin 12(13) EpoME), Hepoxilins (HxA3, HxB3), 19(20) EDPE, 
17(18) EETeE, 2(14(15) EET)-EG and 14(15) EET-EA by EH4, when compared to control infected 
cells.  
To investigate whether there was a slight enzymatic activity of EH4 in the lysate, that was masked by 
the background activity of Sf9 cells, a screening for potential inhibitors of endogenous hydrolase 
activity was performed. This inhibitor should block background activity in order to reveal putative 
hydrolase activity of EH4. It was shown that juvenile hormone epoxide hydrolase (JHEH) from 
manduca sexta has 64% similarity to human mEH (Wojtasek and Prestwich 1996). Therefore, Sf9 
endogenous EH is most likely a membrane associated enzyme. Screening for endogenous inhibitors 
was carried out with different mEH inhibitors. As figure 5-22 shows, valpromide is a potent inhibitor of 
endogenous hydrolase activity in Sf9 cells, and incubation with 5mM valpromide reduces endogenous 
activity about 98%. First experiments aiming at the determination of IC50 values indicated an inhibition 
of 50% at approximately 500µM (figure 5-23). 
 
 
Figure 5-22: Inhibitor screen for endogenous EH in Sf9 cells. Mock 
transfected Sf9 cells were disrupted by French® Pressure Cell press and 
preincubated with different inhibitors (5mM) for 5 minutes on ice. Turnover 
of 8(9) EET (5µM) for 30 minutes was measured by LC-MS/MS. 
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Attempts to measure EH4 activity at simultaneous inhibition of endogenous activity with 5mM 
valpromide could not demonstrate EH4 specific turnover of EETs (5(6) EET, 8(9) EET, 11(12) EET, 
14(15) EET), EpOMEs (leukotoxin 9(10) EpOME, isoleukotoxin 12(13) EpOME) and Hepoxilins (HxA3, 
HxB3). The level of diol detected in EH4 infected cell lysate was the same as observed in the control. 
Furthermore, the activity in EH4 cell lysate towards EET regioisomers and EpOMEs was inhibited by 
valpromide, indicating that the activity measured in recombinant lysates was a result of endogenous 
EH.  
 
5.1.5.6 Attempts to purify EH4-His from Sf9 lysate 
Western Blot analysis and peptide analysis of Sf9 cell lysates confirmed the presence of EH4-His after 
infection of insect cells as described above. Although EH4 was not overexpressed in Sf9 cells (see 
5.1.5.4) and although the protein is assumed to be membrane bound, attempts to enrich and 
concentrate possible minimal amounts of EH4 from the soluble fraction were made. It is possible that 
the immunological method to detect His-tagged EH4 was not sensitive enough to detect small 
amounts of EH4 in the soluble fraction. EH4 expressing Sf9 cell lysates were submitted to immobilized 
metal-affinity chromatography (IMAC; (Porath, Carlsson et al. 1975) using Ni2+ (BioRad DuoFlow). 
Figure 5-24 shows the histogram of the respective run.  
Figure 5-23: IC50 determination of Valpromide. Sf9 cells infected with 
mock virus were preincubated with valpromide at different concentrations 
for 5 minutes on ice, before adding 5µM substrare (8(9) EET). Enzymatic 
reaction was continued for 30 min at 37°C before an alysis in LC-MS/MS. 
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15µl of the different 1ml fractions (flow-through 2-4 and 32-36, elution 51-66) were analyzed by 
coomassie staining. As illustrated in figure 5-25, fractions 53 to 56 showed a specific eluted band at 
approx. 45kDa, that was also immuno reactive to α-His antibody. However, activity measurements 
with the respective fractions towards EET regioisomers did not show any signs of specific turnover. To 
further confirm the presence of EH4-His and to test whether the eluted protein corresponds to EH4, 
the fractions were digested with trypsin and analyzed by LC-MS/MS. Because the subsequent MRM 
scan failed to detect EH4 specific peptides in the sample, an EMS scan that analyses all peptides that 
are present in the sample was performed. The following BLAST analysis resulted in the detection of 
the endogenous protease Cathepsin L (figure 5-26). 
Results of the mascot Blast search (www.matrixscience.com) pointed towards a Cathepsin L like 
protease from Helicoverpa armigera (Cotton bollworm; Q6UB44_HELAM) with a probability based 
Figure 5-25: Coomassie analysis of the 
elution fraction marked in red (see figure 5-
22). Affinity chromatography resulted in the 
purification of Cathepsin L. 
Figure 5-24: Affinity chromatography of His-tagged EH4 
recombinantly expressed in Sf9 cells. 
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mowse score of 144 (significance level 53) based on three matching queries (peptides shown in red; 
figure 5-26) 
The results suggest that the purified protein is a Sf9 analogue of the Sf21 protease, which was purified 
and characterized by Johnson et al (Johnson and Jiang 2005). The protease is expressed in Sf21 at 
high levels and shares properties with cystein proteases of the papain family. This protein copurifies 
with histidine tagged proteins from Ni2+ affinity columns.  
 
5.1.6 Subcellular localization of EH4 
In order to investigate the subcellular localization and confirm the predicted membrane localization of 
EH4 obtained by in silico analysis, EH4 was analyzed by differential centrifugation as described under 
materials and methods. Figure 5-27 shows the western blot analysis of different subcellular fractions 
and clearly demonstrates that EH4 is present and enriched in all membrane containing fractions. This 
indicates that EH4 is membrane associated. 
 
Figure 5-27 shows that EH4 was enriched and present in membrane fractions. Therefore, activity 
assays with homogenized pellets of EH4 infected Sf9 cells were performed. The objective was to 
Figure 5-26: Mascot search results of the purified protein analyzed by LC-MS/MS. Peptides that 
match with the primary sequence of Cathepsin L like protease of Heliothis armigera are shown in 
red. 
Figure 5-27: Western Blot analysis 
of subcellular localization of EH4-
His recombinantly expressed in 
Sf9 cells. The sample was 
centrifuged at 800g for 15 minutes 
to separate the nucleic fraction (N) 
from the cytosolic fraction (CytoI). 
SN: supernatant. (for details see 
4.7.6) 
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detect enzymatic activity of EH4, which so far might have been missed due to a low enzyme 
concentration. However, LC-MS/MS based activity assays using homogenized pellets failed to prove 
hydrolase activity of EH4 towards EET regioisomers and EpOMEs. 
 
5.1.7 Expression of EH4 in vivo 
In silico analysis of EH4 indicated expression mainly in the central nervous system. In addition, 
expression is present in the respiratory system, the hematological system and the gastro intestinal 
system, as well as in its associated organs. 
To investigate the in vivo expression of EH4, and to confirm the in silico expression data, different 
tissues from mice were analyzed by RT PCR. The tested organs belong to the respiratory system 
(lung), hematological system (blood, spleen), central nervous system (brain), urogenital system 
(kidney), cardiovascular system (heart), muscular system (muscle) and the GI tract (liver). As figure 5 -
 - 28 shows, EH4 is clearly expressed in whole brain homogenate. Other experiments also indicated 
expression in cultured astrocytes, olfactory bulb, blood, liver and lung. However this was less clear 
and validated. Identity of the amplificate obtained by RT PCR from brain was confirmed by sequence 
analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
A 
B 
Figure 5-28: Agarose gel analysis of EH4 
expression in different tissues from mice by RT-
PCR. A: Amplification of EH4 (390 bp), B: 
Amplification of GAPDH (positive control; 523bp). 
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5.2 Functional characterization of EH3 
The second part of this thesis comprises a characterization of the enzymatic activity of EH3 by i) 
analyzing the substrate profile and ii) determination of the kinetic parameters of 8(9) EET, 11(12) EET, 
14(15) EET and 9(10)  EpOME turnover. In addition to that, the effects of established sEH and mEH 
inhibitors on EH3 activity were investigated. 
 
5.2.1 In silico characterization of EH3 
The human EPHX3 gene (GeneID: 79852, HGNC: 23760) is located on human chromosome 19, at 
19p13.12 according to Entrez Gene. Other names of this gene are ABHD9, FLJ22408 and 
MGC131519. The gene contains 7 exons and 6 introns and produces a 1891bp mRNA that encodes 
for a 360 aa protein (40.9kDa) (Thierry-Mieg and Thierry-Mieg 2006). The protein studied in this work 
refers to Q9H6B9 (UniProtKB/Swiss-Prot) and displays an N-terminal signal peptide (aa 1- 35) and a 
predicted glycosylation site at aa 267 (N-linked glycosylation; http://www.uniprot.org/uniprot/Q9H6B9). 
Other in silico analyses point towards a mitochondrial targeting sequence (cleavage site at position 
62) and C-mannosylation at position 110. The EPHX3 gene is present in chimpanzee (99%), dog 
(87%), mouse (83%) and zebra fish (49%) and all share high sequence identity with the human protein 
(% identity given in brackets). The closest c. elegans genes are ceeh-1 (42%) (UniProt accession 
number Q21147) and ceeh-2 (38%) (UniProt: Q21277). The gene is expressed in human tissues, 
mostly in lung, skin, placenta, kidney and brain (Thierry-Mieg and Thierry-Mieg 2006). 
 
5.2.2 Activity assays using LC-MS/MS 
LC-MS/MS was used to demonstrate enzymatic activity of EH3 towards different substrates and to 
determine kinetic parameters.  
 
5.2.2.1 Direct precipitation in acetonitrile 
For LC-MS/MS analysis, the respective analytes need to be solved in acetonitrile. The general method 
was to extract the compounds with ethyl acetate, evaporate the solvent and resolve the analytes in 
acetonitrile. However, the efficacy of extraction with ethyl acetate is a subject to considerable 
variations and thus turned out to be impractical for quantitative analysis and validation of experiments 
in this work. To bypass this problem, a protocol using direct precipitation in acetonitrile was 
established. By using this protocol, the measurement errors based on varying extraction efficacy were 
eluded. Figure 5-29 shows that the precipitation in acetonitrile sufficiently inhibits enzymatic activity of 
EH3. EH3 was incubated with three different EET regioisomers and precipitated after 1 and 10 
minutes. Precipitation inhibits EET hydrolysis as seen in the different amounts of DHETs produced 
after 1 minute as compared to DHET amount produced after incubation for 10min. The ratio 
(10min/1min) for 8(9) EET is 19, for 11(12) EET and 14(15) EET the ratio is 14 and 16, respectively. 
The value obtained is higher than 10, which can be explained by an initial lower temperature. The 
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samples were kept on ice until the substrate was added. This implicates that the assay temperature in 
the first minute might have been lower than 37°C. 
 
5.2.2.2 Precision of EET/DHET quantitation 
For quantitative analysis and determination of kinetic parameters, linearity of DHET detection and the 
calibration curve of the respective transition signals in LC-MS/MS, at least in the field of the 
investigated concentration range, is a basic requirement. Measurement of different DHET amounts 
showed that signal intensities in the range below, as well as above 10µM DHET directly correlate. The 
signal rises linearly with the increase of DHET amount injected on the column (figure 5-30).  
 
Figure 5-29: EH3 was recombinantly expressed in Sf9 cells. FP lysate was incubated with 20µM 
8(9)-, 11(12)- and 14(15) EET at 37°C. After 1 and 10 minutes, 1 volume acetonitrile was added 
to the sample before centrifugation and analysis by LC-MS/MS. In the meantime, the 1 minute 
sample was further incubated at 37°C to test for en zymatic activity in 50% acetonitrile. 
A 
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5.2.3 Substrate profile of EH3 
Epoxyeicosatrienoic acids (EETs) are converted by EH3 to their corresponding diols. Therefore, 
catalytic constants of the respective turnover were determined. Activity assays using other lipid 
epoxides with indicated physiological function were performed in this work, to unveil different 
substrates by which EH3 might intervene with physiological processes. 
 
5.2.3.1 Kinetic parameters of EET turnover 
Epoxyeicosatrienoic acids are important signaling molecules and endogenous substrates of EH3. To 
classify the relevance of EET turnover by EH3, kinetic parameters of EET turnover were determined. 
These parameters were compared to the catalytic constants of sEH and mEH in order to assess the 
physiological impact of EH3. Figure 5-31 shows the kinetic analysis of EET turnover. The results of 
these analyses and a comparison with the previously obtained data of human sEH and mEH 
(Marowsky, Burgener et al. 2009) are given in table 5-7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 5-30: Linearity of DHET signal intensities of different amounts 
injected. The signal rises linearly with the amount of DHET injected 
on the column. 
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 EH3 sEHa mEHa 
8,9-EET    
Vmax [µmol x mg-1 x min-1] 10.47 2.4 0.1 
Km [µM] 28 2 1 
kcat/Km [s-1 x M-1] 2.5 x 105 5 x 105 1 x 105 
    
11,12-EET    
Vmax [µmol x mg-1 x min-1] 40.4 11 0.3 
Km [µM] 78 0.6 0.5 
kcat/Km 3.53 x 105 5 x 106 2 x 105 
    
14,15-EET    
Vmax [µmol x mg-1 x min-1] 51.2 20 0.025 
Km [µM] 128 2 0.25 
kcat/Km 2.75 x 105 5 x 106 1 x 105 
Table 5-7: Comparison of kinetic parameters of EET turnover by EH3, 
mEH and sEH. Vmax and KM were determined by kinetic modeling. 
 
a: Catalytic constants of EET turnover from the recombinant mouse 
enzyme reported previously (Marowsky, Burgener et al. 2009). 
 
Table 5-7 shows that the catalytic efficacy of EET turnover (8(9) EET, 11(12) EET, 14(15) EET) by 
EH3 is in the same order of magnitude as those of mEH and sEH. In fact the Vmax values of EH3 are 
higher, but since enzymes generally catalyze reactions below Km, the ratio Kcat over Km is the relevant 
value.  
Figure 5-31: Hydrolysis of different EET regioisomers by EH3. EH3 
expressing Sf9 cells were disrupted by French® Pressure cell press and 
assay was performed as described in materials and methods. Results of 
the analysis are given in the table below. 
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The resulst show that all analyzed substrates were converted by EH3 with high Vmax and Km. This 
resulted in catalytic efficacies that are in the range of those that were reported for mEH. Turnover of 
5(6)-EET was not analyzed, because insect cell preparations displayed a significant background 
activity with this particular substrate. All other EET regioisomers remained essentially stable in the 
presence of insect cell homogenates that were infected with control virus. 
 
5.2.3.2 Other substrates of EH3 
Screening for possible epoxides as substrates for EH3 revealed other endogenous mediators that are 
hydrolyzed by EH3. Figure 5-32 depicts the turnover of leukotoxin and isoleukotoxin (12(13) EpOME), 
as well as the two hepoxilins HxA3 (Hepoxilin A3) and HxB3 (Hepoxilin B3). The diagram displays the 
formation of the corresponding diols (DiHOMEs and Trioxilins) in % of total turnover. 
The well established sEH inhibitor AUDA (12-(3-adamantan-yl-ureido) dodecanoic acid) is an inhibitor 
of EH3 enzymatic activity as described below (5.2.5). This inhibitor was used to specifically ascribe the 
respective turnover to EH3, and to discriminate EH3 activity from a background activity. Within the 
investigated time period of 15 min, the formation of leukotoxin - diol (9(10) DiHOME) was the highest 
with 70% of total leukotoxins being hydrolyzed. In contrast, only 4% Hepoxilin B3 was converted to the 
corresponding Trioxillin B3. Both substrates, isoleukotoxin and Hepoxilin A3, were hydrolyzed to the 
same amount (15%).  
Finally a series of other lipid derived epoxides was investigated. First experiments in this study 
indicated that EH3 is also capable of hydrolyzing the 14(15) epoxide of arachadinoyl ethanol amide 
14(15) EET-EA. This is a potential CYP450 metabolite of the cannabinoid receptor agonist 
Figure 5-32: Specific activity of EH3 towards leukotoxins (9(10) and 12(13) 
EpoME) and hepoxilins (Hepoxilin A3 and B3). The activity is shown as 
formation of the respective diols after 15min. Inhibition with the sEH inhibitor 
AUDA leads to significant decrease of diol formation, demonstrating that the 
turnover is EH3 specific. 
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anandamide (figure 5-33). Turnover of 14(15) EET-EA by EH3 resulted in 40 times the formation of 
the respective diol than in control cells. Hydrolysis with hsEH served as positive control. 
In contrast to the above investigated substrates, EH3 wasn’t capable of hydrolyzing 17(18) EpETE, 
19(20) EDPE and 2-14(15)-epoxy glycerol (2-14(15) EG, data not shown). There was no difference 
between EH3 expressing cells and control infected Sf9 cells in turnover of 17(18) EpETE and 19(20) 
EDPE. In addition to that, inhibition with 1µM AUDA had not effect on the amount of diol produced. 
This indicates that EH3 is not involved in the formation of the respective diol. Results from 2(14(15)-
EET) EG turnover indicated, that Sf9 cells display endogenous 2-EG esterase activity. 14(15) EET as 
well as 14(15) DHET were detected in the cell lysates after incubation with the glycerol ester derivate. 
Most probably, endogenous esterases hydrolyze 2(14(15)-EET) EG into 14(15) EET. 14(15) EET in 
turn is hydrolyzed by EH3 to the corresponding diol 14(15) DHET. This is an explanation for the 
detection of 14(15) EET and 14(15) DHET in this assay. Hence the analysis of hydrolase activity of 
EH3 towards this particular substrate is not possible in Sf9 cell lysates. 
A detailed determination of kinetic parameters of 14(15) EET-EA turnover in the given time frame was 
not considered due to the high costs of the respective substrate. 
 
5.2.3.3 Kinetic parameters of Leukotoxin turnover 
Leukotoxin is an endogenous lipid mediator and a substrate of EH3 that is efficiently hydrolyzed by 
EH3 (70% turnover after 15 min) as shown above (5.2.3.2). As it displays important physiological 
function in development of ARDS, the respective kinetic parameters of leukotoxin turnover by EH3 
were determined (figure 5-34). Leukotoxin is converted by EH3 with a Vmax of 20.67 µmol mg-1 x min-1 
and a Km of 25.2 µM. 
 
Figure 5-33: Hydrolysis of the epoxy metabolite of arachadinoyl 
ethanol amide, 14(15) epoxy arachadinoyl ethanol amide (14(15) 
EET-EA). Control cells only show marginal amounts of the respective 
diol compared to EH3 expressing Sf9 cells. 
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Table 5-8 shows a comparison of the catalytic constants of EH3 with those of sEH and two c. elegans 
enzymes, which were investigated by Harris and colleagues recently (Harris, Aronov et al. 2008). 
The catalytic efficacy (Kcat / Km) of 9(10)  EpOME turnover by EH3 is slightly higher than that of sEH 
and about an order of magnitude higher than that of ceeh-1. Ceeh-2 shows only very low turnover of 
leukotoxin with a catalytic efficacy of 1.2 x 103 M-1x s-1. 
 
 EH3 sEHc,b ceeh-1b ceeh-2b 
Leukotoxin (9(10)  EpOME)     
Vmax [µmol x mg-1 x min-1] 20.67 2.78 0.137 6.7 x 10-3 
Km [µM] 25 6.15 7.5 8.4 
kcat/Km [M-1x s-1] 5.6 x 105 4.5 x 105 2.9 x 104 1.2 x 103 
 
Table 5-8: Kinetic parameters of leukotoxin (9(10)  EpOME) turnover by EH3, sEH and the c. 
elegans orthologous ceeh-1 and ceeh-2. Vmax and Km of EH3 were determined by kinetic modeling 
as described in materials and methods. Values of sEH, ceeh-1 and ceeh-2 are taken from the results 
published by Harris et al. (b) (Harris, Aronov et al. 2008) and Greene (c) (Greene, Williamson et al. 
2000). 
 
5.2.4 Quantification of EH3  
For determination of the kinetic parameters of EET turnover by EH3, in particular Vmax and kcat, the 
amount of EH3 present in the investigated cell lysate needs to be determined. To calculate the protein 
concentration, EH3 was first expressed in bacteria. The concentration of recombinant EH3 was 
calculated based on serial dilutions of BSA. Secondly, a western blot with known EH3 concentration 
was performed to calculate western blot signals from the Sf9 cell lysates.  
 
 
Figure 5-34: Hydrolysis of leukotoxin (9(10) EpoME) by EH3. EH3 
expressing Sf9 cells were disrupted by French® Pressure cell 
press and assay was performed as described in materials and 
methods. Results of the analysis are given in the table below. 
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5.2.4.1 Expression of EH3 in E. coli 
For recombinant expression of EH3 in E .coli, a pRSETb expression vector that contains the full length 
EH3 cDNA (EH3 (FL)) was generated by EcoRI / NcoI cloning, using an EH3 containing plasmid 
(provided by Michael Arand). This vector was used as template for amplification of anchorless EH3 
(primer #15 and #16; details and PCR conditions see appendix). The resulting PCR fragment was 
subcloned into PCR4 Topo vector. Since the NcoI restriction site in this EH3 containing vector turned 
out to be spontaneously mutated during PCR amplification and therefore was not applicable for further 
cloning into pRSETb, the vector was digested with EcoRI and alternatively cloned into pRSETc. For 
generating the respective pRSETb construct, a KasI/EcoRI fragment of Topo-EH3 was cloned into a 
pRSETb construct that was produced earlier (pRSETb EH3 frameshift; figure 5-35).  
 
This earlier produced construct includes a single mutation at position 528, which leads to a frameshift 
and thus premature termination of translation. This finally results in a truncated EH3 protein with 146 
aa (sequence see appendix). Both anchorless proteins (pRSETbEH3, pRSETcEH3) were 
overexpressed (figure 5-36), whereas the full length protein was not. 
 
Figure 5-35: Cloning diagram for generation of EH3 expression constructs. 
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5.2.4.2 Determination of EH3 amount present in Sf9 cell lysate 
For quantifying the EH3 amount that is present in Sf9 lysates, His- tagged EH3, that was expressed in 
E. coli, was used as a standard to calibrate Western Blot signals of Sf9 lysates. The amount of His-
tagged EH3 present in bacterial inclusion bodies was calculated based on a BSA calibration curve 
(figure 5-37).  
 
Calibration of BSA signals (figure 5-38) revealed 1.6 area counts per ng BSA. This value was used to 
quantify the protein amount of EH3 expressed in E. coli (figure 5-39). 
Different dilutions of EH3 inclusion bodies (in 10 µl endvolume each) were analyzed by coomassie 
staining (5-39 A) and density was measured by ImageJ (figure 5-39 B). Signal intensity increased with 
dilution factor (R2=0.9934). Calculation of density signals revealed a concentration of 0.6 µg/µl of EH3 
in the above used inclusion body suspension. 
 
Figure 5-37: Coomassie staining of BSA and EH3 separated on 
SDS-Page (12.5%). A dilution series of 0.25µg – 2µg BSA was 
loaded on the gel to quantify the amount of EH3 present in 
different dilutions of inclusion bodies. 
Figure 5-36: Expression of anchorless EH3 in 
BL21DE3. Expression was induced at OD600~ 
0.4 with 1mM IPTG and continued for 4h at 
37°C. Bacterial cells were resuspended in 
assay buffer and disrupted by French® 
Pressure Cell Press. Lysate was centrifuged for 
20min at 4000 rpm to spin down inclusion 
bodies. 
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Figure 5-39: Quantification of EH3 expressed in E. coli. Inclusion 
bodies were washed in 20mM TE buffer and different dilutions were 
submitted to SDS-Page (12.5%) and analyzed by coomassie staining 
(A). Evaluation of signal density was performed using ImageJ (B). 
B 
A 
Figure 5-38: Calibration of BSA density signals from coomassie 
staining using ImageJ. BSA (0.25 µg - 2 µg) was loaded on 
12.5% PAA gel and stained with coomassie (A). Calibration 
curve of BSA density signal after analysis with ImageJ (B). 
B 
A 
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Subsequently, different amounts (1.25 ng - 20 ng) of EH3 protein were analyzed by western blot, and 
density signals of EH3 were evaluated by ImageJ. Comparison of the signals from Sf9 cell lysates with 
the signals of known EH3 concentration was used to determine the concentration of EH3 present in 
the samples that were used for activity assays and determination of kinetic parameters.  
 
 area counts ng on blot  ng/µl 
charge II (2.5 µl) 1082 0.7  0.28 
charge II (5µl) 1609 1.3  0.27 
charge I (2.5µl) 1239 0.8  0.32 
charge I (5µl) 1833 1.5  0.3 
Table 5-9: Calculation of the EH3 protein amount present in the Sf9 cell lysate. 
 
Figure 5-40 shows the western blot used to quantify the respective amount of EH3 present in the 
insect cell lysate. Different amounts (1.25ng – 20ng) of EH3 were used as a standard to quantify the 
protein amount of Sf9 lysates (charge I and II). The calibration curve of EH3 was best described by 
non linear regression of an allosteric sigmoid modeling (5-40 B). This is a routine modeling provided 
by the PRISM® software. Based on this modeling and the signal density obtained for Sf9 samples, the 
Figure 5-40: Quantification of EH3 expressed in Sf9 lysate (charge I and II) 
using ImageJ. Different amounts (1.25 – 20ng) of EH3 were immunoblotted 
(A) to calibrate density signals for quantification of EH3 present in Sf9 lysates 
(B). The outlier was not included in linear regression. 
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amount of EH3 present in the Sf9 lysate was calculated. This resulted in a concentration in the insect 
cell lysates of 0.31 ng/µl EH3 (charge I) and 0.27 ng/µl (charge II) respectively (table 5-9). 
 
5.2.5 Inhibitor profile of EH3 
Inhibition of EET turnover by sEH is regarded as a promising tool for maintaining the beneficial effects 
of EETs and hence for application in treatment of diverse EET linked diseases like hypertension and 
inflammation. Various inhibitors have been developed and tested for their potential as marketable 
drug. Several representative sEH inhibitors (sEHi) and mEH inhibitors (mEHi) have been analyzed 
towards their inhibitory effect on EH3 enzymatic activity. 
 
5.2.5.1 AUDA and structure related sEHi inhibit EH3 enzymatic activity 
To investigate the effect of established sEHi and mEHi on enzymatic activity of EH3, cell lysates were 
preincubated with different inhibitors and turnover of 8(9) EET was measured after 10 minutes. As 
table 5-10 shows, enzymatic activity of EH3 is affected and reduced by AUDA and by the structurally 
related sEH inhibitors # 950 and # 1214 to 5.5%, 18% and 38% respectively. The established sEHi 
ACU and # 1675 (t-AUCB) did not affect EH3 activity. Likewise elaidamide, a well known mEH 
inhibitor, did not show any effect on turnover of 8(9) EET by EH3. As expected, all sEHi significantly 
reduced enzymatic activity of hsEH. However, the apparent stimulating effect of elaidamide on hsEH 
is surprising and cannot be explained.  
As illustrated in table 5-10, compounds #950 (1-Adamantan-1-yl-3-{5-[2-(2-
ethoxyethoxy)ethoxy]pentyl}-urea) and #1214 (8-(3-Adamantan-1-yl-ureido)-octanoic acid) share fatty 
acid like structure with AUDA (12-(3-adamantan-yl-ureido) dodecanoic acid) and are potent inhibitors 
of EH3 activity. These findings may give a hint to the substrate spectrum and preference of EH3 for 
slim, fatty acid derived epoxy compounds displaying an aliphatic chain. The inhibition of EH3 
enzymatic activity by elaidamide is not significant (p-value: 0.071) due to the high variation in the 
vehicle control (22%). 
 
RESULTS 
_________________________________________________________________________________ 
 
83
 
5.2.5.2 IC50 determination of AUDA 
Since treatment with 1µM AUDA strongly inhibits EH3 and almost completely diminishes the formation 
of 8(9) DHET, the IC50 of AUDA was determined (figure 5-41). AUDA inhibits EH3 enzymatic activity 
with an IC50 of 100nM, which is well in the range to have the enzyme affected under the experimental 
conditions usually employed for in vivo sEH inhibition (e.g. Dorrance, Rupp et al. 2005). 
Table 5-10: Inhibitory effects of different sEH and mEH inhibitors on 
enzymatic activity of EH3 and hsEH. EH3 (0.3 ng/µl) and hsEH (0.5 ng/µl) was 
preincubated with the respective inhibitor before addition of 8(9) EET (5 µM) 
for 10 min at 37°C. The residual activity in % of t he vehicle control was 
determined in triplicate (± standard deviation; students t-test: * p<0.05, 
**p<0.005). 
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5.2.6 Expression of EH3 in vivo 
To investigate the expression pattern of EH3 in the mammalian organism, mRNA was isolated from 
different mouse organs and analyzed for EH3 expression. In addition, human total protein western 
blots with samples from brain, uterus, lung, kidney, spleen and placenta, were submitted to 
immunoblotting with EH3 specific antibody. Reverse transcriptase PCR revealed strongest expression 
of EH3 in lung and heart. Moreover expression in kidney, muscle and brain was detectable. However 
this was less significant and reproducible.  
Figure 5-41: IC50 determination of AUDA on enzymatic activity of EH3. Inhibition was 
analyzed in two independent experiments in duplicates. EH3 expressing Sf9 cells were 
preincubated with AUDA in different concentrations for 5 minutes before 8(9) EET was 
added and hydrolysis was enabled for 10min at 37°C.  Samples were analyzed by LC-
MS/MS and activity compared to vehicle control (100%) was calculated. 
Figure 5-42: Western blot of 
different human protein lysates 
against EH3. There is a distinct 
band at 56kDa visible in lung, 
kidney and placenta.  
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Western blot analysis of total human protein lysates showed a single immunoreactive band in lung, 
kidney and placenta (figure 5- 42). Although the band seems to be specific, the molecular weight of 
56kDa is higher than expected for EH3 (40.1 kDa) and could be explained by glycosylation of EH3. 
However, expression of EH3 in lung, kidney and placenta is in line with available human expression 
data (www.genesapiens.org).  
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6 DISCUSSION 
6.1 Expression of EH4 and EH3 in E. coli 
The expression of EH3 as well as EH4 in E. coli turned out to be difficult during this work. Two 
different observations were made: i) proteins that contain the membrane anchor are not expressed in 
E. coli and ii) N - terminal fusion of truncated protein promotes overexpression in bacteria. The only C-
terminal tagged protein that could be expressed in E. coli was EH4-3/3. This protein consists of 95 C-
terminal amino acids and lacks the membrane anchor and most of the α/β - hydrolase fold structure. 
This suggests that the membrane anchor and/or features of the N-terminal amino acids inhibit proper 
expression and folding of the protein.  
The fact that anchorless N-terminal tagged EH3 protein led to visible overexpression in bacteria, 
whereas the N-terminal tagged full length EH3 protein (including the membrane anchor) was not 
expressed in E. coli, indicates that the putative membrane anchor is critical for protein expression. A 
direct comparison between the two expression constructs pGEFGSTN-EH4AB and pGEFHisCEH4AB 
further shows, that the N-terminal tag promotes expression. Both constructs only differ in the location 
of the tag, but encode for the same protein. Yet only the N-terminal tagged protein was expressed in 
E. coli.  
The two enzymes, EH3 and EH4, are membrane associated and display a membrane anchor within 
the N-terminal amino acids. It is commonly known that bacterial expression of proteins, in particular 
membrane proteins, can involve difficulties (Baneyx and Mujacic 2004; Wagner, Bader et al. 2006). 
The correct folding of newly synthesized proteins is supported by molecular chaperones, molecules 
that mediate refolding or unfolding as well as solubilization of proteins, by shielding hydrophobic 
domains from the cytoplasmic environment. It has been shown that some membrane proteins require 
membrane-specific chaperones, which might not be present in bacterial cells. If the protein does not 
rapidly reach native conformation or interacts with a folding modulator, the consequence is either 
proteolytic degradation or deposition into inclusion bodies (Baneyx and Mujacic 2004). Proteolytic 
degradation might be one reason why the expression of full length EH3 and EH4 protein is not 
possible in E. coli. Other explanations are negative selection by the recombinant protein, mRNA 
instability or hindrance of the translation initiation. A negative selection of the E. coli cells that express 
EH3 or EH4 is not very likely, because GST-EH4 and His-EH3 contain all catalytically active amino 
acids and yet they are overexpressed in bacterial cells. Difficulties in translation, either on the level of 
mRNA stability or initiation of translation are more likely. Protein synthesis is often regulated at the 
level of translation initiation, which depends on the binding of initiation factors and ribosomal subunits. 
In prokaryotic cells, natural mRNA contains so called Shine-Dalgarno (SD) sequences that form base 
pairs with specific bases in the 16S rRNA, and thereby augment translation initiation by anchoring the 
30S rRNA (Kozak 1999). In absence of such interaction the translation initiation might be inefficient 
and protein synthesis is hindered. Besides the upstream SD sequences, there are also downstream 
sequences that influence translation initiation by interacting with 16S rRNA. It was demonstrated, that 
the so called DB (Downstream Box) sequence can likewise stimulate translation, independent form the 
SD sequences (Sprengart, Fuchs et al. 1996). It is feasible that N-terminal fusion to GST or Histidine 
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might enhance interaction of the 16S rRNA with the start codon and thus promote translation initiation 
of EH3 and EH4. This would explain why the N-terminal fusion of EH4 resulted in overexpression, 
whereas the C-terminal tagged EH4 could not be expressed.  
Both proteins, EH3 and EH4 were also expressed in eukaryotic expression systems. In contrast to 
recombinant expression in E. coli, the expression of full length C-terminal tagged and non-tagged EH3 
and EH4 was possible in insect cells. The baculovirus based expression system is an established 
system for overexpression of heterologous proteins in insect cells. Yet, expression of EH3 and EH4 
was rather low (approx. 0.1%), although other EHs were successfully overexpressed in this 
expression system (oral communication with Prof. Arand). Since the expression of EH4 in Cos-7 and 
V79 cells was verified only at mRNA level, it is not clear whether the expression of non-tagged full 
length protein implicates difficulties in these cells. 
 
6.2 Detection of EH4  
The rabbit immunization with either truncated protein or synthetic peptides failed to obtain an immune 
serum that specifically detects EH4 from E. coli and insect cell lysates. This might be due to the high 
conservation of the amino acid sequence between human EH4 and rabbit EH4. The ensemble rabbit 
genome assembly contains an EPHX4 related gene (www.ensembl.org) for which one transcript is 
recorded (ENSOCUP00000015012). This transcript encodes for a 159 amino acid peptide that aligns 
with aa 201-362 of the human EH4 protein and shows a sequence identity of 94% (see 8.7). The 
truncated protein used for immunization contained aa 267-362 and therefore is highly similar to the 
rabbit protein. A highly conserved sequence might not trigger the expected immune reaction. 
Alternatively, an LC-MS/MS based method was established to detect EH4. The analysis of methanol 
extracted peptides resulted in more significant hits, compared to the peptides obtained after tryptic 
digestion and extraction from PAA gel. Most probably the tryptic in gel digest is less sufficient, since 
the trypsin has to diffuse into the gel first. In addition to that, there might be a loss of peptides during 
the extraction process of the peptides from the PAA gel. 
Several experiments aimed at the detection of the peptide that contains the putative catalytic 
nucleophile. This would open the possibility to screen for genuine substrates by LC-MS/MS. EH4 
expressing tissue homogenates, e.g. brain homogenates, could then be directly denatured in 
methanol and peptides could be analyzed by the specific MRM scan. The increase in mass of the 
specific peptide would then give information on the nature of the substrate that is covalently bound 
and “trapped” to the catalytic nucleophile. In principal, this method has been applied in the work of Dr. 
Annette Cronin in our group, to identify the catalytic aspartate of sEH phosphatase domain (Cronin, 
Homburg et al. 2008). 
 
6.3 Activity assays of EH3 and EH4 
The N-terminal fusion of GST to EH4 enabled overexpression of the theoretically active protein in 
E.coli. Thus the enzymatic activity towards styrene 7, 8 oxide (STO) was investigated in recombinant 
E. coli lysates. Activity measurements towards STO showed that GST itself has enzymatic activity 
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because radioactivity was detected in the aqueous phase of recombinant GST lysates. Most likely this 
is a result of GSH conjugation to STO. It has been shown that glutathione transferases conjugate GSH 
to styrene oxide (Hayakawa, Lemahieu et al. 1974; Hiratsuka, Yokoi et al. 1989) and that GSH is 
present in E. coli (Apontoweil and Berends 1975). Although rather few research exists on bacterial 
GST enzymes, Iizuka et al. (Iizuka, Inoue et al. 1989) purified GST from E. coli B, which showed 
specific activity towards CDNB. However, they are not quantitatively prominent enzymes in these cells 
and the activity was significantly lower than those from mammals, plants and fungi. It is conceivable 
that the radioactivity measured in the aqueous phase originated from a GSH conjugate of STO, either 
catalyzed by recombinant expressed GST or endogenous GST from E. coli. It is not possible to 
discriminate between endogenous and recombinant GST with the performed assay. However, thin 
layer chromatography with radiolabeled phenylglycol as standard and preceding incubation with e.g. 
CDNB to deplete GSH, would be an approach to identify the product in the aqueous phase as either 
conjugate or possible hydrolysis product. There is one reference that describes a bacterial enzyme 
from Mesorhizobium loti, called FosX , that is likewise able to hydrolyze the natural antibiotic 
fosfomycin and to form a GSH conjugate in the presence of GSH (Fillgrove, Pakhomova et al. 2003). 
Although it is very unlikely that the GST from S. japonicum used for fusion to EH4 displays similar 
activity, the expression system was excluded from further activity experiments, because a clear 
discrimination between GST produced diol and EH4 produced diol would not have been possible. An 
alternative expression system that was used for recombinant expression in this work was stable 
transfection of the mammalian cell lines Cos-7 and V79. A variety of experiments to detect enzymatic 
activity of EH4 in mammalian cells failed. The system was excluded from activity experiments, 
because Cos-7 cells exhibited endogenous activity towards EETs. The background activity is most 
likely mediated by sEH, which is present in these cells as reported and observed in different studies 
(Sandberg, Hassett et al. 2000; Fang, Hu et al. 2006). Furthermore it must be taken into account that 
presence of EH4 in Cos-7 as well as V79 cells was only demonstrated on mRNA level.  
The use of Sf9 cells as expression system for enzymatically active EH4 was the most promising 
approach, since EH3 has been successfully expressed in Sf9 cells in active form. Yet, the performed 
experiments did not allow to demonstrate hydrolase activity of EH4 towards various substrates. 
Attempts to detect significant EH4 specific turnover in whole recombinant Sf9 cell lysates as well as in 
fractions of membrane proteins failed. Based on the assumption that EH4 has epoxide hydrolase 
activity, there are three possible explanations for the absence of enzymatic activity: (i) the enzyme is 
lacking cofactors which are required for catalysis, (ii) the enzyme is inactively expressed or (iii) the 
enzyme has a restricted substrate spectrum and the relevant compound has not been tested yet. It is 
very unlikely that EH4 requires a cofactor for enzymatic conversion, since all known α/β hydrolase fold 
EHs mediate cofactor independent hydrolysis. In contrast, it cannot be excluded that the enzyme is 
expressed in inactive form. It is possible that the protein is present in protein aggregates, which would 
also be an explanation for the results obtained by differential centrifugation. It is not possible to 
differentiate native membrane association from protein aggregates with this experiment. If the protein 
is indeed located in the mitochondria as predicted by in silico analysis, the correct folding and activity 
might depend on adequate targeting and/or organelle specific proteins. In absence of these proteins 
the recombinant expressed enzyme cannot acquire proper folding. Hydrophobic residues are then 
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exposed to the aqueous phase, which results in clustering of the proteins and the subsequent 
formation of aggregates. However, protein aggregation has not been observed for recombinant 
expression in Sf9 cells of any epoxide hydrolase so far.  
Regarding the possible substrates for EH4, there are many different fatty acid derived epoxides 
present in the organism, and the elucidation of novel pathways constantly reveals alternative 
molecules, which might be substrates for EH4. The clear expression of EH4 in the brain and eye 
suggested DHA derived epoxides as possible substrates, since DHA is one of the most abundant fatty 
acids in the brain and enriched in synapses and retina (Hong, Gronert et al. 2003; Mukherjee, 
Marcheselli et al. 2007). However, the 19(20) epoxide of DHA was not turned over by EH4. Yet, there 
are other possible compounds arising from novel pathways of DHA to docosatriens and resolvins, e.g. 
4(5), 7(8) and 16(17) epoxy intermediates that still might be relevant substrates for EH4 (Hong, 
Gronert et al. 2003).  
It can be excluded that the His-Tag is responsible for the lack of enzymatic activity, because all activity 
assays were likewise performed with full length non-tagged EH4. It is also possible that endogenous 
enzymes present in the insect cell lysate show higher activity than EH4, and thus EH4 activity can not 
be detected. Blocking of endogenous activity was an approach to unveil possible marginal EH4 
activity. Insect cell lysates were preincubated with valpromide, which turned out to reduce the 
endogenous turnover of Sf9 cells. However, it must be taken into account that in those experiments 
EH4 might have been equally affected by valpromide. In this case EH4 activity still remained 
undetected. In terms of EH3, endogenous activity of Sf9 cells did not affect determination of EH3 
kinetic parameters, since the background activity was in the range of 0.5% - 1.5% of EH3 turnover. 
This had no relevant influence on the obtained catalytic constants. Another possible reason for 
inactivity of EH4 might be an amino acid exchange at position 321. The NCBI Ace View database 
annotates a SNP (single nucleotide polymorphism) that leads to a Y321F variant of EH4. The EH4 
protein investigated in this work contains a phenylalanine residue at position 321, which is not present 
in other mammalian species. Extensive sequence comparison during writing of this thesis showed, 
that Y321 is highly conserved in other species like chimpanzee, cow, mouse, dog, chicken and zebra 
fish (an alignment is given in 8.7). There are also human cDNA clones that contain a tyrosine residue 
at position 321. A detailed analysis of the underlying cDNA clones revealed, that only one human 
reference sequence (NM_173567, BC041475) showed the amino acid exchange. This argues against 
a polymorphism of EH4 and rather points towards a mutation in the respective cDNA clone. However, 
this was not expected, since the officially available IMAGE clone is based on this mutated reference 
sequence. It is not very likely that F321 has an effect on the catalytic activity of the enzyme. F321 is 
positioned between the α/β hydrolase fold and the lid domain, a region which should not influence the 
catalytic site. However, it must be taken into account that the amino acid exchange might lead to 
conformational changes and thereby affects enzymatic activity. One approach to investigate the 
relevance of Y321 for enzymatic activity of EH4 would be a respective nucleotide exchange in the 
expression plasmid by use of QuickChange® PCR. Recombinant expression of the resulting EH4 
Y321 and subsequent enzymatic activity assays should unveil the relevance of Y321 for enzymatic 
activity of EH4.  
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6.4 Subcellular localization of EH4 
To investigate the subcellular localization and the predicted membrane localization, His- tagged EH4 
was submitted to differential centrifugation and analyzed by western blot. The western blot results of 
the experiment can only be interpreted qualitatively and not quantitatively, since cellular fractionation 
as performed in this work is not able to clearly isolate the different subcellular compartments from 
each other. There is a tendency to a higher concentration of EH4 in mitochondrial membranes 
observed, which coincides with the in silico results that indicate a mitochondrial target sequence. Yet, 
a clear mitochondrial location still needs to be demonstrated, since there was no mitochondrial marker 
used in this experiment. As already mentioned above, formation of protein aggregates could also be 
an explanation for the results obtained in western blot analysis. Likewise, immuno reactive bands 
would be observed in all membrane associated fractions, because protein aggregates are insoluble 
and thus present in the respective pellet. Since aggregated proteins are denatured and hence inactive, 
this would also explain an absence of enzymatic activity.  
 
6.5 Expression of EH3 and EH4 in vivo 
EH4 mRNA was detected in whole brain homogenate from adult mice, which is in line with the in vivo 
expression data available at the Allen Mouse Brain Atlas (Lein, Hawrylycz et al. 2007). A detailed 
analysis of the expression summary shows highest expression of EH3 in cortex, hippocampus and 
olfactory bulb. Furthermore, Stansberg et al. generated a global expression map in rat brain and 
showed that Abhd7 (now designated EPHX4, see (Decker, Arand et al. 2009) is significantly enriched 
in the cortex (Stansberg, Vik-Mo et al. 2007). A close examination of the cDNAs underlying the data 
available on expression databases (e.g. EST Profile at UniGene) showed that most reference 
sequences derive form cortical probes (e.g. CJ059344, CJ059344, CJ059315, BY255071) of neonates 
(Okazaki, Furuno et al. 2002; Carninci, Kasukawa et al. 2005). The expression of EH4 is clearly 
focused on the central nervous system and not to the liver or other xenobiotic metabolizing organs, 
which indicates a physiological role of EH4 rather than a function in detoxification.  
In vivo expression of EH3 in mice was demonstrated in lung and heart in previous work in our group. 
In silico analysis furthermore indicated significant expression of EH3 in skin and tongue of mice. 
Detailed examination of the available expression data points towards restricted expression of the gene 
to a particular cell type within these organs. Toulza et al. (Toulza, Mattiuzzo et al. 2007) investigated 
the human epidermal transcriptome and demonstrated that EH3 is highly expressed only in late 
granular keratinocytes. Granular keratinocytes comprise the most terminally differentiated, viable cell 
layer. These cells are characterized by the expression of numerous genes that are involved in skin 
barrier formation, which suggests a role of EH3 in cornification. Furthermore, available reference 
sequences from tongue of adult mice were extracted only from taste buds (e.g. EH105600), which 
points towards a role of EH3 in taste reception. Attempts to demonstrate EH3 mRNA in skin and 
tongue of adult mice failed during this work. This might be the result of the restricted expression 
pattern or an altered expression depending on the developmental state. 
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Since there is no specific antibody against EH4 available, protein analysis was only performed in 
terms of EH3 expression. There was a single immuno reactive band visible in human samples from 
lung, kidney and placenta, but the expected molecular weight differs from the one observed in the 
western blot. The bands were detected at 56 kDa instead of 40 kDa. One explanation for the shift in 
molecular weight is glycosylation. Glycosylation of EH3 was also indicated by in silico analysis. A 
possible approach to investigate glycosylation of proteins is the treatment with PGNaseF. This is an 
endoglycosidase that removes all N-linked glycosylation. Since western blot in human tissues 
indicated expression in placenta, commercially available total protein and membrane protein fractions 
of human placenta were analyzed towards glycosylation of EH3. Unfortunately, it was not possible to 
confirm the expression of EH3 in the placenta samples. Therefore it remains to be investigated if EH3 
is indeed glycosylated in lung, kidney and placenta, and if glycosylation causes the molecular weight 
shift.  
 
6.6 What is the role of EH3 in the human organism? 
The initial question was if EH3 is a detoxifying enzyme or a physiological regulator. Previous 
experiments have shown that EH3 hydrolyzes the fatty acid derived 9(10) epoxystearic acid, but not 
the generic EH substrate STO and the steroid epoxides 5(6) and 24(25) cholesterolepoxide. This led 
to the assumption that EH3 is more likely involved in the turnover of fatty acid derived endogenous 
epoxides. This work shows that 8(9) EET, 11(12) EET, 14(15) EET and 9(10) EpOME (leukotoxin) are 
converted by EH3 with a catalytic efficacy comparable to that of sEH. In addition to that, EH3 is 
capable to hydrolyze 12(13) EpOME (isoleukotxin), Hepoxilin A3 as well as B3 and 14(15) EET-EA to 
their corresponding diols. This spectrum of substrates, together with that of inhibitors, suggests that 
slim, fatty acid derived molecules are preferentially converted by EH3. The fact that EH3 does not 
convert 19(20) EDPE and 17(18) EET indicates that the distance between the epoxide and the 
carboxylic head of the substrate might be critical for proper binding to the active site, and thus affects 
the catalytic turnover. The tested substrate spectrum raises no claims to completeness since it might 
well be that there are other structurally related epoxides which are converted by EH3 but have not 
been tested yet.  
To date, research only focused on sEH as major player in the turnover of endogenous epoxides to 
regulate physiological processes. The hydrolysis of hepoxilins by EH3 is a possible indicator towards a 
role of EH3 in human hepoxilin metabolism. Hepoxilins are involved in differentiation of the skin and in 
skin barrier function (Brash, Yu et al. 2007; Epp, Furstenberger et al. 2007; Yu, Schneider et al. 2007). 
Moreover mutations in the coding regions of hepoxilin generating enzymes correlate with a congenital 
form of ichthyosis, a genetic skin disorder which is characterized by dry, thickened and scaly skin 
(Jobard, Lefevre et al. 2002; Eckl, Krieg et al. 2005). The in silico expression analysis of EH3 points 
towards expression in the skin which is in line with the study from Toulza et al., that demonstrated 
expression of EH3 in human late granular keratinocytes (Toulza, Mattiuzzo et al. 2007). An 
association of EH3 with skin disorder was shown by a comparative study of human disease genes, 
which predicts EH3 as a candidate gene for ichthyosis (Ala, Piro et al. 2008). There are also reports 
that point towards an EET mediated function of EH3 in granular keratinocytes. As proved in the 
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present work, EH3 is able to efficiently hydrolyze 11(12) EET and 14(15) EET to their corresponding 
diols. Both EET regioisomers are present in murine late skin keratinocytes (Keeney, Skinner et al. 
1998) and have been suggested to regulate epidermal cornification by the activation of 
transglutaminase in situ (Ladd, Du et al. 2003). Transglutaminase mediates the cross linking of 
scaffold proteins and keratin filaments to form the cornified cell envelope. In this study, 14(15) EET 
increased formation of the cornified envelope by activating transglutaminase in mouse and human 
epidermal keratinocytes. It is feasible that the hydrolysis of 14(15) EET by EH3 might lead to 
decreased transglutaminase activity and hence reduce cornification. On the contrary, inactivation and 
null mutations in the human transglutaminase gene can cause a form of lamellar ichthyosis. The sum 
of these findings suggest a role of EH3 in skin differentiation and the construction of the water 
impermeable barrier in the cornified layer of the epidermis.  
Aberrant de novo methylation of CpG islands is a characteristic of human cancers and is found early 
during carcinogenesis (Jones and Baylin 2002). The CpG islands in the promoter region of EPHX3 
have been shown to be methylated in melanoma cell lines compared to cultured human epidermal 
melanocytes (Furuta, Nobeyama et al. 2006), as well as in primary gastric cancer and multiple gastric 
cancer cell lines (Yamashita, Tsujino et al. 2006). Furthermore, the gene EPHX3 is considered as 
prognostic marker for prostate cancer with aggressive growth properties. The methylation level of CpG 
islands of the EPHX3 promoter is increased in patients with early recurrence of prostate cancer 
compared to those patients who did not suffer from recurrence (Cottrell, Jung et al. 2007). This 
suggests a cancer promoting effect of EH3, yet the role of EH3 in prostate cancer has not been 
investigated. All available data regarding the role of arachidonic acid derivatives in prostate cancer is 
limited to the COX and LOX pathways, which is the prostaglandins and the enzymes themselves.  
Not only decreased or absent activity, but also excessive activity of EH3 could present a problem, 
because the hydrolysis of leukotoxin to leukotoxin-diol seems to be an activating process. As different 
in vitro and in vivo studies demonstrate, leukotoxin-diol is the more toxic reagent and responsible for 
the severe outcome of ARDS in leukotoxin diol treated mice (Moghaddam, Grant et al. 1997; Moran, 
Weise et al. 1997; Zheng, Plopper et al. 2001). A role of EH3 in the genesis of ARDS is feasible, 
because the catalytic efficacy of leukotoxin turnover is in the range of sEH and EH3 is well expressed 
in the lung. This was shown by western blot analysis of human total lung protein as well as RT PCR 
analysis and in silico data. So far, the impact and relevance of EH3 in turnover of lipid derived 
epoxides was unregarded in research. Therefore most AUDA sensitive effects are ascribed to sEH. 
Theoretically, the observed AUDA sensitive in vivo effects could at least be partly mediated by EH3, 
as long as plasma concentrations are sufficiently high to affect EH3. Smith et al. showed that tobacco 
induced lung inflammation in rat is reduced by AUDA when given before and after exposure (Smith, 
Pinkerton et al. 2005). The blood concentration of AUDA after 3 days of daily injection was between 
152 nM and 325 nM, a concentration that is sufficient to affect EH3 enzymatic activity. Hence it cannot 
be excluded that EH3 also plays a role in attenuation of tobacco smoke induced lung inflammation, 
because EH3 equally hydrolyzes anti - inflammatory EETs and is inhibited by AUDA.  
EH3 becomes important for the development of sEHi and the human organism. The enzyme is 
affected by a subclass of sEHi and involved in physiological processes by hydrolysis of endogenous 
biologically active epoxides. For this reason, the so far sEH specific inhibitors must be divided into 
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sEH specific and sEH/EH3-mixed inhibitors. The degree to which EH3 has impact on the development 
of sEHi based therapeutics remains to be seen, because the exact physiological relevance of this 
novel enzyme is not clear yet. 
EH3 gained interest as marker for early cancer prognosis, in particular prostate cancer. The fact that 
EH3 is hypermethylated in many cancers suggests, that a decreased or absent activity of EH3 has 
tumor promoting effects. Once the enzymatic activity and physiological role of EH3 is more elucidated 
and investigated in detail, the development of novel therapeutics that increase or maintain EH3 activity 
might represent a promising approach towards the treatment of cancer  
The results of the substrate screening, the inhibitor profiling and the fact that catalytic efficacies are in 
the same range as those of sEH, strongly suggests a role of EH3 in physiological regulation. 
 
6.7 Is EH4 a novel epoxide hydrolase? 
Two recently reported characterized epoxide hydrolases from c. elegans are similar to the novel EH s 
that were identified in humans. Ceeh-1 and ceeh-2 share 40% sequence identity and have significant 
similarity to human sEH. The enzymes display enzymatic activity towards EETs as well as leukotoxin 
9(10) EpOME and isoleukotoxin 12(13) EpOME (Harris, Aronov et al. 2008). Interestingly, the catalytic 
efficacy of ceeh-1 and ceeh-2 differ by factor 24 (leukotoxin) and 10 (isoleukotoxin), respectively. 
Likewise the Vmax towards turnover of 14(15), 11(12) and 8(9) EET by ceeh-2 is much lower than that 
of ceeh-1 (factor 80, 29 and 20 respectively). It seems possible that similar to ceeh-2 and ceeh-1, EH4 
only shows very low enzymatic activity towards the tested substrate as compared to EH3. The only 
study that points towards physiological relevance of EH4 states that the gene is directly regulated and 
repressed by ZNF217, an oncogene that is overexpressed in many cancer types and thought to act as 
transcriptional repressor (Krig, Jin et al. 2007). The high sequence identity to EH3 and the 
comparatively high conservation of EH4 among different species strongly suggest that EH4 is an 
epoxide hydrolase with physiological function. It is feasible that the protein has a very narrow 
substrate spectrum and only converts few substrates with particular structure, since expression of EH3 
is also rather restricted to the central nervous system.  
 
6.8 Conclusion and outlook 
The two novel identified epoxide hydrolases EH3 and EH4 are closely related (45%), but obviously 
differ in their substrate spectrum and enzymatic activity towards endogenous derived epoxides.  
Various experiments could not prove enzymatic activity of EH4 with the tested substrates and the 
expression systems used in this work. It seems possible that EH4 shows very low enzymatic activity 
towards the tested substrates and only displays efficient turnover towards a particular substrate of so 
far unknown structure. Identification of EH4 substrates, in order to elucidate the function and the role 
of EH4 in the human organism, presents the future challenge. One approach could be the 
identification of the physiological substrate by “trapping“ the substrate to the catalytic nucleophile. An 
LC-MS/MS analysis of the respective peptide could then give information on the covalently bound 
substrate. For this approach, a method to detect the peptide that contains the catalytic nucleophile has 
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to be established first. The increase in mass of this peptide can then provide information about the 
compound that is bound to the nucleophile. Furthermore, the generation of an antibody against EH4 
would enable protein analysis in different tissues from mice and at the same time allow validating the 
results that were observed by differential centrifugation. The cellular localization of EH4 in stable 
transfected cells could be directly investigated by immuno fluorescence. The optimization of 
expression and purification of GST-EH4 would be a promising approach for the generation of an 
antibody.  
It has been shown that EH3 is rather a physiological regulator like sEH, than a detoxifying epoxide 
hydrolase similar to mEH. Present results are compatible with the substrate spectrum of EH3 being 
restricted to fatty acid derived epoxides. Furthermore, hitherto sEH specific inhibitors need to be 
classified into sEH specific and sEH/EH3 mixed inhibitors. The effects of mixed sEH/EH3 inhibitors 
used as therapeutics need to be investigated and evaluated in the future. In terms of ARDS, inhibition 
of EH3 might have positive effects. In terms of cancer development, a decrease in EH3 activity also 
might have negative effects, as suggested by the hypermethylated CpG islands which are observed in 
different cancer cells. Differences in expression pattern, regulation and substrate preference between 
sEH and EH3 are likely and need to be further investigated in order to evaluate the in vivo effects of 
sEH/EH3 mixed inhibitors. The generation of an EH3 knock out mouse would provide a useful tool for 
analysis of the different inhibitor effects and to investigate the physiological role of EH3. Further 
investigations are needed to fully understand the role of EH3 for the human organism and to unveil the 
signaling pathways that are involved. This would help to further understand diseases like ARDS, 
ichthyosis or cancer. Eventually this might enable the development of novel therapeutics that 
specifically target at EH3 and can be used for treatment of these diseases. 
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8 APPENDIX 
8.1 Primer sequences and PCR conditions  
8.1.1 Cloning of expression constructs 
 
# label  sequence 
1 nEH2 F EcoRV 1509 (sense) 5`- cgccgcgatatcccaatggcgaggctgcg -3` 
2 nEH2 R BamHI 1509 (antisense) 5`- caggatccctcattacagacccttcatagaag -3` 
3 hE for-mem (sense) 5`- cagatcatgacgcccgcgtgcctgagcgac -3` 
4 nEH2 R for Ab Bgl II (antisense) 5`- gtagatctggagtggtcaccatgtgatg -3` 
5 nEH2 1/3 F 140606 (sense) 5`- gatatccccatggcgaggc -3` 
6 nEH2 1/3 R 140606 (antisense) 5`- gtgctacaactagatcttcact -3` 
7 nEH2 3/3F (sense) 5`- catgccatggtcttttctcagcctggag -3` 
8 nEH2 3/3R (antisense) 5`- gatcagatctccatctttttttcttgtttcttc -3` 
9 nEH2 F (BamHI) IRAK 210108 (sense) 5`- catgggatccgcctcccaatggcgaggctgcggga -3` 
10 nEH2 R (PstI) pFastBac (antisense) 5`- aaagaactgcagatctttttttcttgtttcttcttttagaaatgtcc -3` 
11 nEH2 F (NdeI) IRAK 200807 (sense) 5`- cgccgcctccatatggcgaggctgcggga -3` 
12 nEH2 R (PstI) pFastBac (antisense) 5`- aaagaactgcagatctttttttcttgtttcttcttttagaaatgtcc -3` 
13 pFastModify for (sense) 5`- ggttggctacgtatactccg -3` 
14 pFastModify rev (antisense) 5`- gcactgcaggatccgaattcatatgtataggtttttttattacaaaactgttacg -3` 
15 EH3 anchorless (sense) 5`- ccatgggcgggcgccgtcggag -3` 
16 EH3revprset (antisense) 5`- tatagaattcagcaaggaccactagtcc -3` 
 
 
 
Table 8-1: Primer sequence of the primers used to generate the EH3 and EH4 expression constructs. 
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PCR conditions: 
 
primers prim. denaturation denaturation annealing elongation final elongation cycles 
# 1 / # 2 95°C 03:00 95°C 00:45 62°C 00:45 72°C 01: 00 72°C 10:00 30 
# 3 / # 4 95°C 03:00 95°C 00:45 62°C 00:45 72°C 01: 00 72°C 10:00 30 
# 5 / # 6 95°C 02:00 95°C 00:45 56.4°C 00:30 72°C 0 1:20 72°C 05:00 35 
# 7 / # 8 95°C 02:00 95°C 00:45 56.4°C 00:30 72°C 0 1:20 72°C 05:00 35 
# 9 / # 10 95°C 01:30 95°C 00:45 64°C 00:45 72°C 01 :00 72°C 03:00 30 
# 11 / # 2 95°C 01:30 95°C 00:45 60.8°C 00:45 72°C 01:00 72°C 03:00 30 
# 11 / # 10 95°C 01:30 95°C 00:45 60.8°C 00:45 72°C  01:00 72°C 03:00 30 
# 13/ # 14 95°C 01:30 95°C 00:45 59.7°C 00:45 72°C 01:00 72°C 03:00 30 
# 15 / # 16 95°C 03:00 95°C 00:45 63°C 00:30 72°C 0 1:00 72°C 10:00 28 
Table 8-2: PCR conditions used to amplify the respective cDNA for generation of different expression constructs. The primer pair given in the first column 
specifies the PCR reaction as mentioned in the text (see tables 5-1, 5-3 and 5-4). 
 
8.1.2 RT-PCR 
 
label  sequence 
nEH2 (sense) 5`-GAG GCA TGA TTG CCT GGC TGA TTG C-3` 
nEH2 (antisense) 5`-GCA GTG TTG GGG TGG TCA CCA TGT G-3` 
GAPDH (sense) 5`-CCT GCA CCA CCA ACT GCT TA-3` 
GAPDH (antisense) 5`-ACC ACC CTG TTG CTG TAG CC-3` 
Table 8-3: Sequences of EH4 and GAPDH specific primers used for expression analysis by reverse transcriptase PCR. 
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primers prim. denaturation denaturation annealing elongation final elongation cycles 
nEH2(RT1) / nEH2(RT2) 95°C 02:00 95°C 00:45 55°C 00 :45 72°C 01:00 72°C 10:00 25 
GAPDH sense/GAPDH antisense 95°C 02:00 95°C 00:45 62°C 00:45 72°C 01:00 72°C 10 :00 30 
Table 8-4: PCR conditions for specific amplification of EH4 and GAPDH cDNA. 
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8.2 DNA sequences 
8.2.1 EH3 
 
 
 
Figure 8-1: cDNA sequence of EH3. 
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8.2.2 EH4 
 
 
 
Figure 8-2: cDNA sequence of EH4 (EPHX4). 
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8.3 Protein sequences 
 
8.3.1 EH4 
 
 
Figure 8-3: Amino acid sequence of EH4. Indicated in blue is the putative membrane anchor, the 
presumed catalytically active residues are indicated in grey. 
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Figure 8-4: Amino acid sequence of EH4. Indicated in red are the two observed variants (annotated 
as SNPs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-5: Translation and amino acid sequence of pFastBacModnEH2 (Amod) construct. The 
resulting protein contains all putative enzymatic active residues and the membrane anchor. 
APPENDIX 
_________________________________________________________________________________ 
110 
 
8.3.2 His-tagged EH4 proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-6: Translation and amino acid sequence of nEH2AB_HisC (EH4AB-HisC) construct. The 
EH4 protein contains a C-terminal His-tag (6x) and is lacking the membrane anchor and the putative 
catalytically active amino acid D306 (proton donor) and H336 (proton acceptor). 
Figure 8-7: Translation and amino acid sequence of nEH2_3/3-His construct. The truncated EH4 
protein consists of the amino acids 267-362. The construct is lacking the catalytic nucleophile D169.  
Figure 8-8: Translation and amino acid sequence of nEH2_1/3-His construct. The truncated EH4 
protein consists of amino acids 1-118 and is lacking all putative catalytically active residues. 
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Figure 8-9: Translation and amino acid sequence of pFastBacHis-nEH2 (Y) construct. The full length 
EH4 protein (all features present) is C-terminal tagged (6xHis). 
Figure 8-10: Translation and amino acid sequence of pFastBacmod-nEH2 (Bmod) construct. The full 
length EH4 protein (all features present) is C-terminal tagged (6xHis). 
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8.3.3 His tagged EH3 proteins 
 
 
 
 
 
 
 
 
Figure 8-11: Translation and amino acid sequence of pRSETb-EH3 (frameshift) construct. 
Figure 8-12: Translation and amino acid sequence of pRSETb EH3 (FL). 
Figure 8-13: Translation and amino acid sequence of pRSETc EH3. 
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8.3.4 GST tagged EH4 proteins 
 
Figure 8-14: Translation and amino acid sequence of pRSETbEH3. 
Figure 8-15: Translation and amino acid sequence of pGEFGSTN-nEH2AB construct. EH4 protein is 
N-terminally fused to GST and lacks the membrane anchor. EH4 protein starts at position 230 (PACL). 
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8.4 Vector sequences (MCS)  
8.4.1 pGEF-HisC 
 
 
Figure 8-16: Translation and amino acid sequence of pGEFGSTN-nEH2AB construct. EH4 protein is 
N-terminally fused to GST and lacks the membrane anchor. EH4 protein starts at position 230 (PACL) 
and is lacking the catalytic residues D306 (proton donor) and H336 (proton acceptor). 
Figure 8-17: Multiple cloning site (MCS) of pGEF-HisC. 
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8.4.2 pGEF-GSTN 
 
8.4.3 pFastBacHis 
 
 
Figure 8-18: Multiple cloning site of pGEF-GSTN. The selected translation (PRGSAM) indicates the open 
reading frame of GST protein. 
Figure 8-19: MCS of pFastBacHisC. 
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8.4.4 pFastBacHismod 
 
 
 
 
8.4.5 pRSET B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-20: MCS of pFastBacmod. 
Figure 8-21: MCS of pRSET B (source: www.invitrogen.com). 
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8.4.6 pRSET C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-22: MCS of pRSET C (source: www.invitrogen.com) 
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8.5 Vectormaps 
8.5.1 Vectors 
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8.5.2 EH4-constructs 
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8.5.3 EH3-constructs 
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8.6 LC-MS/MS Data 
 
8.6.1 Cos-7 background activity 
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Figure 8-23: Turnover of EET regioisomers by cos-7 and analysis by LC-MS/MS. 1x106 cells 
were resuspended in NH4HCO3 buffer. 10µl were added to 90µl substrate (3µM EET) and 
incubated for 15 minutes at 37°C. 100 µl ethylacetate was added to stop enzymatic reaction and 
to extract diols. Ethyl acetate was evaporated under a stream of nitrogen and resolved in 100µl 
acetonitrile before analysis by LC-MS/MS. 
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8.6.2 V-79 activity assay (LC-MS/MS) 
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Figure 8-24: turnover of EET regioisomers by V79 cells and analysis by LC-MS/MS. 1x106 cells 
were resuspended in NH4HCO3 buffer. 10µl were added to 90µl substrate (3µM EET) and 
incubated for 15 minutes at 37°C. 100 µl ethylacetate were added to stop enzymatic reaction 
and to extract diols. Ethyl acetate was evaporated under a stream of nitrogen and resolved in 
100µl acetonitrile before analyzed by LC-MS/MS. 
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8.6.3 EH3 turnover of 2-14(15) EET Ethanolamide 
 
 
 
 
 
Figure 8-25: Turnover of 2-14(15) EET ethanol amide by sEH (see 4.9.2 for details). 
Figure 8-26: Turnover of 2-14(15) EET ethanol amide by mock infected Sf9 cells (see 4.9.2 for 
details).  
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Figure 8-27: Turnover of 2-14(15) EET ethanol amide by EH3 (see 4.9.2 for details).  
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8.6.4 LC-MS/MS conditions for peptide analysis 
 
MRM conditions for the identification of EH4 peptides on a QTrap 4000 using a MIDAS 
workflow integrated into the Analyst 1.4.2 acquisition method 
 
Total transitions: 92  
Dwell time: 14 ms  
Total cycle time, including product ion scan: 3.22s  
Monitoring criteria: Charge state: 1+, 2+ and 3+, 1 missed cleavage; 400 – 2000 m/z.  
 
 
 
MRM tab 
 
 
 
 
 
 
 
 
 
 
 
 
Q1 and Q3 resolutions set to UNIT, settling time 2ms, pause between mass ranges 5.007 ms  
 
 
 
 
 
 
 
Source / Gas 
Curtain gas (CUR)  25 
Collision gas (CAD)  10 
IonSpray Voltage (IS)  5000 
Ion Source Gas1 (GS1)  40  
Ion Source Gas2 (GS2)  50  
Temperature (TEMP) 450 
Compound  
Declustering Potential (DP) 50  
Entrance Potential (EP) 10 
Collision Cell Exit Potential (CXP) 15 
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IDA criteria tab 
  
Select 3 of the most intense peaks 
Threshold setting 200 cps  
Exclude former target ions after 3 occurrences for 20 s  
Mass tolerance 250 mmu  
Exclude isotopes within 4 amu  
 
EPI tab 
Source / Gas 
Curtain gas (CUR)  25  
Collision gas (CAD)  HIGH  
IonSpray Voltage (IS)  5000 
Ion Source Gas1 (GS1)  40  
Ion Source Gas2 (GS2) 50  
Temperature (TEMP) 450 
 
Compound 
Declustering Potential (DP) 50 
Collision Energy Spread (CES) 5 
Collision Energy (CE) 60 
 
MS  
Start (amu) Stop (amu) Time (s) 
50  280  0.0575 
275  2000 0.4313 
Total Scan Time (1 scans)  0.6023 s  
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Advanced MS  
Scan Mode  Profile  
Step Size (amu)  0.12  
Q1 Resolution  Unit  
Scan Rate (amu/s)  4000  
Intensity Threshold (counts)  0  
Settling Time (ms)  2  
Pause between mass ranges (ms)  5.007  
Q3 Energy Barrier (v)  8  
Dynamic Fill Time  ON  
 
Detected peptides 
Sequence Start  End Q1 Mass Q3 Mass CE 
LLWSLGK 39 45 816,5 590,3 56,4 
FHYVAAGER 83 91 525,3 602,3 30,2 
FHYVAAGER 83 91 1049,5 602,3 69,9 
GYGETDAPI 129 139 608,3 593,3 34,2 
GYGETDAPI 129 139 608,3 708,4 34,2 
GYGETDAPI 129 139 1215,6 593,3 79,5 
GYGETDAPI 129 139 1215,6 708,4 79,5 
DILDSLGYSK 153 162 1110,6 654,3 73,4 
DILDSLGYSK 153 162 1110,6 567,3 73,4 
LIVINFPHPN 189 206 729,1 564,3 25 
LIVINFPHPN 189 206 729,1 1154,6 25 
HPAQLLK 207 213 806,5 501,3 55,8 
HLFTSHSTGI 240 251 656,8 727,4 36,5 
HHMVTTPTL 292 319 1077,2 1384,6 35,1 
HHMVTTPTL 292 319 1077,2 1742,8 35,1 
LTILSEASHW 328 348 812,4 685,4 27,4 
LTILSEASHW 328 348 812,4 1297,7 27,4 
LTILSEASHW 328 348 1218,1 685,4 63,5 
LTILSEASHW 328 348 1218,1 1297,7 63,5 
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8.7 Alignments 
 
 
 
 
 
 
 
 
Figure 8-28: Amino acid alignment of EH4 from different species. There are different human protein sequences available of which one shows the Y321E variant (encircled in red). 
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Figure 8-29: Alignment of EH4-3/3 with rabbit homologue. 
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ABBREVIATIONS 
aa  amino acid 
ARDS  acute respiratory distress syndrome 
AUDA  12-(3-adamantan-1-yl-ureido) dodecanoic acid  
CDNB  1-chloro-2,4-dinitrobenzene 
CDU  1-cyclohexyl-3-dodecyl-urea 
ChEH  cholesterol epoxide hydrolase 
DCU  N,N-dicyclohexylurea 
DHA  docosahexenoic acid 
DHET  dihydroxyeicosatetraenoic acid 
EDHF  endothelium derived hyperpolarization factor 
EDPE  epoxy docosapentaenoic acid 
EET   epoxy eicosatrienoic acid 
EET-EA EET-ethanol amide 
EETeE  epoxy eicosatetraenoic acid 
EH  epoxide hydrolase 
EH3  novel epoxide hydrolase 3 
EH4   putative epoxide hydrolase 4 
EPA  eicosapentaenoid acid 
FP  french pressure cell press 
GSH  Glutathione 
GST  Glutathione -Transferase 
HAD  haloalkane dehalogenase 
HxA3  Hepoxilin A3 
HxB3  Hepoxilin B3 
LB  lysogeny broth (luria broth) 
LEH  limonene epoxide hydrolase 
LOX  lipoxygenase 
LTA4  Leukotriene A4 
MCS  multiple cloning site 
mEH  microsomal epoxide hydrolase 
mock  infected with Rv… 
ON  over night 
PUFA  polyunsaturated fatty acid 
ROS  reactive oxygen species 
RT  room temperature 
sEH  soluble epoxide hydrolase 
sEHi  sEH inhibitor(s) 
STO  styrene  7,8 - oxide 
WB  western blot
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